1
|
Schrijver DP, Röring RJ, Deckers J, de Dreu A, Toner YC, Prevot G, Priem B, Munitz J, Nugraha EG, van Elsas Y, Azzun A, Anbergen T, Groh LA, Becker AMD, Pérez-Medina C, Oosterwijk RS, Novakovic B, Moorlag SJCFM, Jansen A, Pickkers P, Kox M, Beldman TJ, Kluza E, van Leent MMT, Teunissen AJP, van der Meel R, Fayad ZA, Joosten LAB, Fisher EA, Merkx M, Netea MG, Mulder WJM. Resolving sepsis-induced immunoparalysis via trained immunity by targeting interleukin-4 to myeloid cells. Nat Biomed Eng 2023; 7:1097-1112. [PMID: 37291433 PMCID: PMC10504080 DOI: 10.1038/s41551-023-01050-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 05/02/2023] [Indexed: 06/10/2023]
Abstract
Immunoparalysis is a compensatory and persistent anti-inflammatory response to trauma, sepsis or another serious insult, which increases the risk of opportunistic infections, morbidity and mortality. Here, we show that in cultured primary human monocytes, interleukin-4 (IL4) inhibits acute inflammation, while simultaneously inducing a long-lasting innate immune memory named trained immunity. To take advantage of this paradoxical IL4 feature in vivo, we developed a fusion protein of apolipoprotein A1 (apoA1) and IL4, which integrates into a lipid nanoparticle. In mice and non-human primates, an intravenously injected apoA1-IL4-embedding nanoparticle targets myeloid-cell-rich haematopoietic organs, in particular, the spleen and bone marrow. We subsequently demonstrate that IL4 nanotherapy resolved immunoparalysis in mice with lipopolysaccharide-induced hyperinflammation, as well as in ex vivo human sepsis models and in experimental endotoxemia. Our findings support the translational development of nanoparticle formulations of apoA1-IL4 for the treatment of patients with sepsis at risk of immunoparalysis-induced complications.
Collapse
Affiliation(s)
- David P Schrijver
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
| | - Rutger J Röring
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Jeroen Deckers
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Anne de Dreu
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Yohana C Toner
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Geoffrey Prevot
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Bram Priem
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- Angiogenesis Laboratory, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam, the Netherlands
| | - Jazz Munitz
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Eveline G Nugraha
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Yuri van Elsas
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Anthony Azzun
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Tom Anbergen
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Laszlo A Groh
- Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Anouk M D Becker
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Tumor Immunology, RIMLS, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Roderick S Oosterwijk
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Boris Novakovic
- Epigenetics Group, Murdoch Children's Research Institute, Royal Children's Hospital and Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia
| | - Simone J C F M Moorlag
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Aron Jansen
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
| | - Peter Pickkers
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
| | - Matthijs Kox
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Intensive Care Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
| | - Thijs J Beldman
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
| | - Ewelina Kluza
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Mandy M T van Leent
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Abraham J P Teunissen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Roy van der Meel
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Zahi A Fayad
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Leo A B Joosten
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Medical Genetics, Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
| | - Edward A Fisher
- Division of Cardiology, Department of Medicine, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY, USA
| | - Maarten Merkx
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Mihai G Netea
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.
- Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands.
- Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany.
| | - Willem J M Mulder
- Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.
- Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the Netherlands.
| |
Collapse
|
2
|
Maier A, Toner YC, Munitz J, Sullivan NAT, Sakurai K, Meerwaldt AE, Brechbühl EES, Prévot G, van Elsas Y, Maas RJF, Ranzenigo A, Soultanidis G, Rashidian M, Pérez-Medina C, Heo GS, Gropler RJ, Liu Y, Reiner T, Nahrendorf M, Swirski FK, Strijkers GJ, Teunissen AJP, Calcagno C, Fayad ZA, Mulder WJM, van Leent MMT. Multiparametric Immunoimaging Maps Inflammatory Signatures in Murine Myocardial Infarction Models. JACC Basic Transl Sci 2023; 8:801-816. [PMID: 37547068 PMCID: PMC10401290 DOI: 10.1016/j.jacbts.2022.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2022] [Revised: 12/29/2022] [Accepted: 12/29/2022] [Indexed: 08/08/2023]
Abstract
In the past 2 decades, research on atherosclerotic cardiovascular disease has uncovered inflammation to be a key driver of the pathophysiological process. A pressing need therefore exists to quantitatively and longitudinally probe inflammation, in preclinical models and in cardiovascular disease patients, ideally using non-invasive methods and at multiple levels. Here, we developed and employed in vivo multiparametric imaging approaches to investigate the immune response following myocardial infarction. The myocardial infarction models encompassed either transient or permanent left anterior descending coronary artery occlusion in C57BL/6 and Apoe-/-mice. We performed nanotracer-based fluorine magnetic resonance imaging and positron emission tomography (PET) imaging using a CD11b-specific nanobody and a C-C motif chemokine receptor 2-binding probe. We found that immune cell influx in the infarct was more pronounced in the permanent occlusion model. Further, using 18F-fluorothymidine and 18F-fluorodeoxyglucose PET, we detected increased hematopoietic activity after myocardial infarction, with no difference between the models. Finally, we observed persistent systemic inflammation and exacerbated atherosclerosis in Apoe-/- mice, regardless of which infarction model was used. Taken together, we showed the strengths and capabilities of multiparametric imaging in detecting inflammatory activity in cardiovascular disease, which augments the development of clinical readouts.
Collapse
Affiliation(s)
- Alexander Maier
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Cardiology and Angiology I, Heart Center of Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Yohana C Toner
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Jazz Munitz
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Nathaniel A T Sullivan
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Ken Sakurai
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Anu E Meerwaldt
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Biomedical Magnetic Resonance Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht/Utrecht University, Utrecht, the Netherlands
| | - Eliane E S Brechbühl
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Geoffrey Prévot
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Yuri van Elsas
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Rianne J F Maas
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Anna Ranzenigo
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Georgios Soultanidis
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Mohammad Rashidian
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Carlos Pérez-Medina
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
| | - Gyu Seong Heo
- Department of Radiology, Washington University, St Louis, Missouri, USA
| | - Robert J Gropler
- Department of Radiology, Washington University, St Louis, Missouri, USA
| | - Yongjian Liu
- Department of Radiology, Washington University, St Louis, Missouri, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA
| | - Filip K Swirski
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Gustav J Strijkers
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Biomedical Engineering and Physics, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
| | - Abraham J P Teunissen
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Claudia Calcagno
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Zahi A Fayad
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Willem J M Mulder
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- Department of Chemical Biology, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Mandy M T van Leent
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Department of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
- Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| |
Collapse
|
3
|
Toner YC, Ghotbi AA, Naidu S, Sakurai K, van Leent MMT, Jordan S, Ordikhani F, Amadori L, Sofias AM, Fisher EL, Maier A, Sullivan N, Munitz J, Senders ML, Mason C, Reiner T, Soultanidis G, Tarkin JM, Rudd JHF, Giannarelli C, Ochando J, Pérez-Medina C, Kjaer A, Mulder WJM, Fayad ZA, Calcagno C. Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation. Sci Rep 2022; 12:6185. [PMID: 35418569 PMCID: PMC9007951 DOI: 10.1038/s41598-022-09590-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Accepted: 03/22/2022] [Indexed: 02/08/2023] Open
Abstract
In recent years, cardiovascular immuno-imaging by positron emission tomography (PET) has undergone tremendous progress in preclinical settings. Clinically, two approved PET tracers hold great potential for inflammation imaging in cardiovascular patients, namely FDG and DOTATATE. While the former is a widely applied metabolic tracer, DOTATATE is a relatively new PET tracer targeting the somatostatin receptor 2 (SST2). In the current study, we performed a detailed, head-to-head comparison of DOTATATE-based radiotracers and [18F]F-FDG in mouse and rabbit models of cardiovascular inflammation. For mouse experiments, we labeled DOTATATE with the long-lived isotope [64Cu]Cu to enable studying the tracer's mode of action by complementing in vivo PET/CT experiments with thorough ex vivo immunological analyses. For translational PET/MRI rabbit studies, we employed the more widely clinically used [68Ga]Ga-labeled DOTATATE, which was approved by the FDA in 2016. DOTATATE's pharmacokinetics and timed biodistribution were determined in control and atherosclerotic mice and rabbits by ex vivo gamma counting of blood and organs. Additionally, we performed in vivo PET/CT experiments in mice with atherosclerosis, mice subjected to myocardial infarction and control animals, using both [64Cu]Cu-DOTATATE and [18F]F-FDG. To evaluate differences in the tracers' cellular specificity, we performed ensuing ex vivo flow cytometry and gamma counting. In mice subjected to myocardial infarction, in vivo [64Cu]Cu-DOTATATE PET showed higher differential uptake between infarcted (SUVmax 1.3, IQR, 1.2-1.4, N = 4) and remote myocardium (SUVmax 0.7, IQR, 0.5-0.8, N = 4, p = 0.0286), and with respect to controls (SUVmax 0.6, IQR, 0.5-0.7, N = 4, p = 0.0286), than [18F]F-FDG PET. In atherosclerotic mice, [64Cu]Cu-DOTATATE PET aortic signal, but not [18F]F-FDG PET, was higher compared to controls (SUVmax 1.1, IQR, 0.9-1.3 and 0.5, IQR, 0.5-0.6, respectively, N = 4, p = 0.0286). In both models, [64Cu]Cu-DOTATATE demonstrated preferential accumulation in macrophages with respect to other myeloid cells, while [18F]F-FDG was taken up by macrophages and other leukocytes. In a translational PET/MRI study in atherosclerotic rabbits, we then compared [68Ga]Ga-DOTATATE and [18F]F-FDG for the assessment of aortic inflammation, combined with ex vivo radiometric assays and near-infrared imaging of macrophage burden. Rabbit experiments showed significantly higher aortic accumulation of both [68Ga]Ga-DOTATATE and [18F]F-FDG in atherosclerotic (SUVmax 0.415, IQR, 0.338-0.499, N = 32 and 0.446, IQR, 0.387-0.536, N = 27, respectively) compared to control animals (SUVmax 0.253, IQR, 0.197-0.285, p = 0.0002, N = 10 and 0.349, IQR, 0.299-0.423, p = 0.0159, N = 11, respectively). In conclusion, we present a detailed, head-to-head comparison of the novel SST2-specific tracer DOTATATE and the validated metabolic tracer [18F]F-FDG for the evaluation of inflammation in small animal models of cardiovascular disease. Our results support further investigations on the use of DOTATATE to assess cardiovascular inflammation as a complementary readout to the widely used [18F]F-FDG.
Collapse
Affiliation(s)
- Yohana C Toner
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Adam A Ghotbi
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Sonum Naidu
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ken Sakurai
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Mandy M T van Leent
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Stefan Jordan
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Institute of Microbiology, Infectious Diseases and Immunology, Berlin, Germany
| | - Farideh Ordikhani
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Letizia Amadori
- Department of Genetics and Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- New York University Cardiovascular Research Center, Department of Medicine, Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA
| | - Alexandros Marios Sofias
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
| | - Elizabeth L Fisher
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alexander Maier
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center Freiburg University, University of Freiburg, Freiburg, Germany
| | - Nathaniel Sullivan
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jazz Munitz
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Max L Senders
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Christian Mason
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- Department of Radiology and Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY, USA
| | - Georgios Soultanidis
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jason M Tarkin
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - James H F Rudd
- Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
| | - Chiara Giannarelli
- Department of Genetics and Genomic Sciences, Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- New York University Cardiovascular Research Center, Department of Medicine, Leon H. Charney Division of Cardiology, New York University Grossman School of Medicine, New York University Langone Health, New York, NY, USA
- Cardiovascular Research Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jordi Ochando
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Carlos Pérez-Medina
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Willem J M Mulder
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands
- Laboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| | - Zahi A Fayad
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Claudia Calcagno
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Ave, PO Box: 1234, New York, NY, 10029, USA.
- Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| |
Collapse
|
4
|
Panizzi P, Krohn-Grimberghe M, Keliher E, Ye YX, Grune J, Frodermann V, Sun Y, Muse CG, Bushey K, Iwamoto Y, van Leent MMT, Meerwaldt A, Toner YC, Munitz J, Maier A, Soultanidis G, Calcagno C, Pérez-Medina C, Carlucci G, Riddell KP, Barney S, Horne G, Anderson B, Maddur-Appajaiah A, Verhamme IM, Bock PE, Wojtkiewicz GR, Courties G, Swirski FK, Church WR, Walz PH, Tillson DM, Mulder WJM, Nahrendorf M. Multimodal imaging of bacterial-host interface in mice and piglets with Staphylococcus aureus endocarditis. Sci Transl Med 2021; 12:12/568/eaay2104. [PMID: 33148623 DOI: 10.1126/scitranslmed.aay2104] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Revised: 05/05/2020] [Accepted: 09/16/2020] [Indexed: 12/24/2022]
Abstract
Acute bacterial endocarditis is a rapid, difficult to manage, and frequently lethal disease. Potent antibiotics often cannot efficiently kill Staphylococcus aureus that colonizes the heart's valves. S. aureus relies on virulence factors to evade therapeutics and the host's immune response, usurping the host's clotting system by activating circulating prothrombin with staphylocoagulase and von Willebrand factor-binding protein. An insoluble fibrin barrier then forms around the bacterial colony, shielding the pathogen from immune cell clearance. Targeting virulence factors may provide previously unidentified avenues to better diagnose and treat endocarditis. To tap into this unused therapeutic opportunity, we codeveloped therapeutics and multimodal molecular imaging to probe the host-pathogen interface. We introduced and validated a family of small-molecule optical and positron emission tomography (PET) reporters targeting active thrombin in the fibrin-rich environment of bacterial colonies. The imaging agents, based on the clinical thrombin inhibitor dabigatran, are bound to heart valve vegetations in mice. Using optical imaging, we monitored therapy with antibodies neutralizing staphylocoagulase and von Willebrand factor-binding protein in mice with S. aureus endocarditis. This treatment deactivated bacterial defenses against innate immune cells, decreased in vivo imaging signal, and improved survival. Aortic or tricuspid S. aureus endocarditis in piglets was also successfully imaged with clinical PET/magnetic resonance imaging. Our data map a route toward adjuvant immunotherapy for endocarditis and provide efficient tools to monitor this drug class for infectious diseases.
Collapse
Affiliation(s)
- Peter Panizzi
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | - Marvin Krohn-Grimberghe
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA.,University Heart Center Freiburg, 79106 Freiburg, Germany
| | - Edmund Keliher
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Yu-Xiang Ye
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Jana Grune
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Vanessa Frodermann
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Yuan Sun
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Charlotte G Muse
- Department of Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, USA
| | | | - Yoshiko Iwamoto
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Mandy M T van Leent
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Anu Meerwaldt
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yohana C Toner
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jazz Munitz
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Alexander Maier
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Georgios Soultanidis
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Claudia Calcagno
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Centro Nacional de Investigaciones Cardivasculares, 28029 Madrid, Spain
| | - Giuseppe Carlucci
- Bernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, NY 10016, USA
| | - Kay P Riddell
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Sharron Barney
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Glenn Horne
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Brian Anderson
- Swine Research and Education Center, Department of Animal Sciences, Auburn University, Auburn, AL 36849, USA
| | - Ashoka Maddur-Appajaiah
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Ingrid M Verhamme
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Paul E Bock
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
| | - Gregory R Wojtkiewicz
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Gabriel Courties
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | - Filip K Swirski
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA
| | | | - Paul H Walz
- Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - D Michael Tillson
- Department of Clinical Science, College of Veterinary Medicine, Auburn University, Auburn, AL 36849, USA
| | - Willem J M Mulder
- Biomedical Engineering and Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| | - Matthias Nahrendorf
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital Research Institute, Harvard Medical School, Boston, MA 02114, USA. .,Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.,Department of Internal Medicine I, University Hospital Würzburg, 97080 Würzburg, Germany
| |
Collapse
|
5
|
Teunissen AJ, Abousaway OB, Munitz J, van Leent MM, Toner YC, Priem B, Senders ML, Pérez-Medina C, Mulder WJ, Rashidian M. Employing nanobodies for immune landscape profiling by PET imaging in mice. STAR Protoc 2021; 2:100434. [PMID: 33899016 PMCID: PMC8056265 DOI: 10.1016/j.xpro.2021.100434] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Noninvasive immunoimaging holds great potential for studying and stratifying disease as well as therapeutic efficacy. Radiolabeled single-domain antibody fragments (i.e., nanobodies) are appealing probes for immune landscape profiling, as they display high stability, rapid targeting, and excellent specificity, while allowing extremely sensitive nuclear readouts. Here, we present a protocol for radiolabeling an anti-CD11b nanobody and studying its uptake in mice by a combination of positron emission tomography imaging, ex vivo gamma counting, and autoradiography. Our protocol is applicable to nanobodies against other antigens. For complete details on the use and execution of this protocol, please see Priem et al. (2020), Senders et al. (2019), or Rashidian et al. (2017).
Collapse
Affiliation(s)
- Abraham J.P. Teunissen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Corresponding author
| | - Omar B. Abousaway
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5418, USA
| | - Jazz Munitz
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mandy M.T. van Leent
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yohana C. Toner
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Bram Priem
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Medical Biochemistry, Amsterdam UMC, Amsterdam 1105 AZ, the Netherlands
- Angiogenesis Laboratory, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam 1105 AZ, the Netherlands
| | - Max L. Senders
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Carlos Pérez-Medina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid 28029, Spain
| | - Willem J.M. Mulder
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Pharmacological Sciences and Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mohammad Rashidian
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215-5418, USA
- Corresponding author
| |
Collapse
|
6
|
Teunissen AJ, van Leent MM, Prevot G, Brechbühl EE, Pérez-Medina C, Duivenvoorden R, Fayad ZA, Mulder WJ. Targeting Trained Innate Immunity With Nanobiologics to Treat Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2021; 41:1839-1850. [PMID: 33882685 PMCID: PMC8159873 DOI: 10.1161/atvbaha.120.315448] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
[Figure: see text].
Collapse
Affiliation(s)
- Abraham J.P. Teunissen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Mandy M.T. van Leent
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Department of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, The Netherlands
| | - Geoffrey Prevot
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Eliane E.S. Brechbühl
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Institute of Materials, School of Engineering (STI), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Raphaël Duivenvoorden
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Zahi A. Fayad
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
| | - Willem J.M. Mulder
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Laboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
| |
Collapse
|
7
|
Bernal A, Calcagno C, Mulder WJM, Pérez-Medina C. Imaging-guided nanomedicine development. Curr Opin Chem Biol 2021; 63:78-85. [PMID: 33735814 DOI: 10.1016/j.cbpa.2021.01.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 01/18/2021] [Accepted: 01/22/2021] [Indexed: 12/14/2022]
Abstract
Nanomedicine research is an active field that produces thousands of studies every year. However, translation of nanotherapeutics to the clinic has yet to catch up with such a vast output. In recent years, the need to better understand nanomedicines' in vivo behavior has been identified as one of the major challenges for efficient clinical translation. In this context, noninvasive imaging offers attractive solutions to provide valuable information about nanomedicine biodistribution, pharmacokinetics, stability, or therapeutic efficacy. Here, we review the latest imaging approaches used in the development of therapeutic nanomedicines, discuss why these strategies bring added value along the translational pipeline, and give a perspective on future advances in the field.
Collapse
Affiliation(s)
- Aurora Bernal
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
| | - Claudia Calcagno
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Willem J M Mulder
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Chemical Biology, Eindhoven University of Technology, Eindhoven, the Netherlands
| | - Carlos Pérez-Medina
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| |
Collapse
|
8
|
van Leent MMT, Beldman TJ, Toner YC, Lameijer MA, Rother N, Bekkering S, Teunissen AJP, Zhou X, van der Meel R, Malkus J, Nauta SA, Klein ED, Fay F, Sanchez-Gaytan BL, Pérez-Medina C, Kluza E, Ye YX, Wojtkiewicz G, Fisher EA, Swirski FK, Nahrendorf M, Zhang B, Li Y, Zhang B, Joosten LAB, Pasterkamp G, Boltjes A, Fayad ZA, Lutgens E, Netea MG, Riksen NP, Mulder WJM, Duivenvoorden R. Prosaposin mediates inflammation in atherosclerosis. Sci Transl Med 2021; 13:eabe1433. [PMID: 33692130 PMCID: PMC8209679 DOI: 10.1126/scitranslmed.abe1433] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Revised: 11/17/2020] [Accepted: 02/17/2021] [Indexed: 12/13/2022]
Abstract
Macrophages play a central role in the pathogenesis of atherosclerosis. The inflammatory properties of these cells are dictated by their metabolism, of which the mechanistic target of rapamycin (mTOR) signaling pathway is a key regulator. Using myeloid cell-specific nanobiologics in apolipoprotein E-deficient (Apoe -/-) mice, we found that targeting the mTOR and ribosomal protein S6 kinase-1 (S6K1) signaling pathways rapidly diminished plaque macrophages' inflammatory activity. By investigating transcriptome modifications, we identified Psap, a gene encoding the lysosomal protein prosaposin, as closely related with mTOR signaling. Subsequent in vitro experiments revealed that Psap inhibition suppressed both glycolysis and oxidative phosphorylation. Transplantation of Psap -/- bone marrow to low-density lipoprotein receptor knockout (Ldlr -/-) mice led to a reduction in atherosclerosis development and plaque inflammation. Last, we confirmed the relationship between PSAP expression and inflammation in human carotid atherosclerotic plaques. Our findings provide mechanistic insights into the development of atherosclerosis and identify prosaposin as a potential therapeutic target.
Collapse
Affiliation(s)
- Mandy M T van Leent
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Experimetal Vascular Biology, Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
| | - Thijs J Beldman
- Experimetal Vascular Biology, Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
| | - Yohana C Toner
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Marnix A Lameijer
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Experimetal Vascular Biology, Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
| | - Nils Rother
- Department of Nephrology and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
| | - Siroon Bekkering
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
| | - Abraham J P Teunissen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Xianxiao Zhou
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Roy van der Meel
- Department of Chemical Biology, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| | - Joost Malkus
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sheqouia A Nauta
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Emma D Klein
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Francois Fay
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Institut Galien Paris-Saclay, Faculté de Pharmacie, CNRS, Université Paris-Saclay, 92 296 Châtenay-Malabry, France
| | - Brenda L Sanchez-Gaytan
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Chemistry Center, Science Institute, Meritorious Autonomous University of Puebla, Puebla 72570, Mexico
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain
| | - Ewelina Kluza
- Department of Chemical Biology, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| | - Yu-Xiang Ye
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
- Department of Diagnostic and Interventional Radiology, University Hospitals Tuebingen, 72076 Tuebingen, Germany
| | - Gregory Wojtkiewicz
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Edward A Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY 10016, USA
| | - Filip K Swirski
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital Research Institute and Department of Radiology, Harvard Medical School, Boston, MA 02114, USA
| | - Bin Zhang
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yang Li
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
- Centre for Individualised Infection Medicine (CiiM) and TWINCORE, joint ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany
| | - Bowen Zhang
- Centre for Individualised Infection Medicine (CiiM) and TWINCORE, joint ventures between the Helmholtz-Centre for Infection Research (HZI) and the Hannover Medical School (MHH), 30625 Hannover, Germany
| | - Leo A B Joosten
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
- Department of Medical Genetics, University of Medicine and Pharmacy, Iuliu Haţieganu, Cluj-Napoca 400000, Romania
| | - Gerard Pasterkamp
- Central Diagnostics Laboratory, Division Laboratories and Pharmacy, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, Netherlands
| | - Arjan Boltjes
- Central Diagnostics Laboratory, Division Laboratories and Pharmacy, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, Netherlands
| | - Zahi A Fayad
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Esther Lutgens
- Experimetal Vascular Biology, Department of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
- Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians Universität, 80331 Munich, Germany
- German Center for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, 80539 Munich, Germany
| | - Mihai G Netea
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
- Department for Genomics and Immunoregulation, Life and Medical Sciences Institute, University of Bonn, 53127 Bonn, Germany
| | - Niels P Riksen
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
| | - Willem J M Mulder
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Internal Medicine and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
- Department of Chemical Biology, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Raphaël Duivenvoorden
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Nephrology and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, Netherlands
| |
Collapse
|
9
|
van Leent MMT, Meerwaldt AE, Berchouchi A, Toner YC, Burnett ME, Klein ED, Verschuur AVD, Nauta SA, Munitz J, Prévot G, van Leeuwen EM, Ordikhani F, Mourits VP, Calcagno C, Robson PM, Soultanidis G, Reiner T, Joosten RRM, Friedrich H, Madsen JC, Kluza E, van der Meel R, Joosten LAB, Netea MG, Ochando J, Fayad ZA, Pérez-Medina C, Mulder WJM, Teunissen AJP. A modular approach toward producing nanotherapeutics targeting the innate immune system. Sci Adv 2021; 7:7/10/eabe7853. [PMID: 33674313 PMCID: PMC7935355 DOI: 10.1126/sciadv.abe7853] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 01/21/2021] [Indexed: 05/07/2023]
Abstract
Immunotherapies controlling the adaptive immune system are firmly established, but regulating the innate immune system remains much less explored. The intrinsic interactions between nanoparticles and phagocytic myeloid cells make these materials especially suited for engaging the innate immune system. However, developing nanotherapeutics is an elaborate process. Here, we demonstrate a modular approach that facilitates efficiently incorporating a broad variety of drugs in a nanobiologic platform. Using a microfluidic formulation strategy, we produced apolipoprotein A1-based nanobiologics with favorable innate immune system-engaging properties as evaluated by in vivo screening. Subsequently, rapamycin and three small-molecule inhibitors were derivatized with lipophilic promoieties, ensuring their seamless incorporation and efficient retention in nanobiologics. A short regimen of intravenously administered rapamycin-loaded nanobiologics (mTORi-NBs) significantly prolonged allograft survival in a heart transplantation mouse model. Last, we studied mTORi-NB biodistribution in nonhuman primates by PET/MR imaging and evaluated its safety, paving the way for clinical translation.
Collapse
Affiliation(s)
- Mandy M T van Leent
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, Amsterdam, Netherlands
| | - Anu E Meerwaldt
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht/Utrecht University, Utrecht, Netherlands
| | - Alexandre Berchouchi
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yohana C Toner
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Marianne E Burnett
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emma D Klein
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Anna Vera D Verschuur
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Sheqouia A Nauta
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Jazz Munitz
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Geoffrey Prévot
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther M van Leeuwen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Farideh Ordikhani
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Vera P Mourits
- Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI), Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
| | - Claudia Calcagno
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Philip M Robson
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - George Soultanidis
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY, USA
- Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Rick R M Joosten
- Center of Multiscale Electron Microscopy, Department of Chemical Engineering and Chemistry, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, Netherlands
| | - Heiner Friedrich
- Center of Multiscale Electron Microscopy, Department of Chemical Engineering and Chemistry, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, Netherlands
- Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands
| | - Joren C Madsen
- Center for Transplantation Sciences and Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
| | - Ewelina Kluza
- Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands
- Laboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands
| | - Roy van der Meel
- Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands
- Laboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands
| | - Leo A B Joosten
- Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI), Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
| | - Mihai G Netea
- Department of Internal Medicine, Radboud Center for Infectious Diseases (RCI), Radboud Institute of Molecular Life Sciences (RIMLS), Radboud University Medical Center, Nijmegen, Netherlands
- Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany
| | - Jordi Ochando
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Zahi A Fayad
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | | | - Willem J M Mulder
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands
- Laboratory of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, Eindhoven, Netherlands
| | - Abraham J P Teunissen
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| |
Collapse
|
10
|
Nahrendorf M, Hoyer FF, Meerwaldt AE, van Leent MMT, Senders ML, Calcagno C, Robson PM, Soultanidis G, Pérez-Medina C, Teunissen AJP, Toner YC, Ishikawa K, Fish K, Sakurai K, van Leeuwen EM, Klein ED, Sofias AM, Reiner T, Rohde D, Aguirre AD, Wojtkiewicz G, Schmidt S, Iwamoto Y, Izquierdo-Garcia D, Caravan P, Swirski FK, Weissleder R, Mulder WJM. Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor 64Cu-Macrin in Mice, Rabbits, and Pigs. Circ Cardiovasc Imaging 2020; 13:e010586. [PMID: 33076700 DOI: 10.1161/circimaging.120.010586] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Macrophages, innate immune cells that reside in all organs, defend the host against infection and injury. In the heart and vasculature, inflammatory macrophages also enhance tissue damage and propel cardiovascular diseases. METHODS We here use in vivo positron emission tomography (PET) imaging, flow cytometry, and confocal microscopy to evaluate quantitative noninvasive assessment of cardiac, arterial, and pulmonary macrophages using the nanotracer 64Cu-Macrin-a 20-nm spherical dextran nanoparticle assembled from nontoxic polyglucose. RESULTS PET imaging using 64Cu-Macrin faithfully reported accumulation of macrophages in the heart and lung of mice with myocardial infarction, sepsis, or pneumonia. Flow cytometry and confocal microscopy detected the near-infrared fluorescent version of the nanoparticle (VT680Macrin) primarily in tissue macrophages. In 5-day-old mice, 64Cu-Macrin PET imaging quantified physiologically more numerous cardiac macrophages. Upon intravenous administration of 64Cu-Macrin in rabbits and pigs, we detected heightened macrophage numbers in the infarcted myocardium, inflamed lung regions, and atherosclerotic plaques using a clinical PET/magnetic resonance imaging scanner. Toxicity studies in rats and human dosimetry estimates suggest that 64Cu-Macrin is safe for use in humans. CONCLUSIONS Taken together, these results indicate 64Cu-Macrin could serve as a facile PET nanotracer to survey spatiotemporal macrophage dynamics during various physiological and pathological conditions. 64Cu-Macrin PET imaging could stage inflammatory cardiovascular disease activity, assist disease management, and serve as an imaging biomarker for emerging macrophage-targeted therapeutics.
Collapse
Affiliation(s)
- Matthias Nahrendorf
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Radiology (M.N., F.F.H., D.R., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Cardiovascular Research Center (M.N., A.D.A.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Internal Medicine I, University Hospital Wuerzburg, Germany (M.N.)
| | - Friedrich Felix Hoyer
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Radiology (M.N., F.F.H., D.R., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Anu E Meerwaldt
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht and Utrecht University, the Netherlands (A.E.M., E.M.v.L.)
| | - Mandy M T van Leent
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (M.M.T.v.L., M.L.S., W.J.M.M.)
| | - Max L Senders
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (M.M.T.v.L., M.L.S., W.J.M.M.)
| | - Claudia Calcagno
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Philip M Robson
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - George Soultanidis
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Carlos Pérez-Medina
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (C.P.-M.)
| | - Abraham J P Teunissen
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Yohana C Toner
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Kiyotake Ishikawa
- Department of Cardiology, Cardiovascular Research Center (K.I., K.F.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Kenneth Fish
- Department of Cardiology, Cardiovascular Research Center (K.I., K.F.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Ken Sakurai
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Esther M van Leeuwen
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht and Utrecht University, the Netherlands (A.E.M., E.M.v.L.)
| | - Emma D Klein
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY
| | - Alexandros Marios Sofias
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway (A.M.S.)
| | - Thomas Reiner
- Department of Radiology and Chemical Biology Program, Memorial Sloan- Kettering Cancer Center, New York, NY (T.R.).,Department of Radiology, Weill Cornell Medical College, New York, NY (T.R.)
| | - David Rohde
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Radiology (M.N., F.F.H., D.R., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Aaron D Aguirre
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Cardiovascular Research Center (M.N., A.D.A.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Wellman Center for Photomedicine (A.D.A.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Gregory Wojtkiewicz
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Stephen Schmidt
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Yoshiko Iwamoto
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - David Izquierdo-Garcia
- Institute for Innovation in Imaging, A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown (D.I.-G., P.C., R.W.)
| | - Peter Caravan
- Institute for Innovation in Imaging, A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown (D.I.-G., P.C., R.W.)
| | - Filip K Swirski
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Radiology (M.N., F.F.H., D.R., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston
| | - Ralph Weissleder
- Center for Systems Biology (M.N., F.F.H., D.R., A.D.A., G.W., S.S., Y.I., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Department of Radiology (M.N., F.F.H., D.R., F.K.S., R.W.), Massachusetts General Hospital Research Institute and Harvard Medical School, Boston.,Institute for Innovation in Imaging, A.A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown (D.I.-G., P.C., R.W.).,Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.)
| | - Willem J M Mulder
- Biomedical Engineering and Imaging Institute (A.E.M., M.M.T.v.L., M.L.S., C.C., P.M.R., G.S., C.P.-M., A.J.P.T., Y.C.T., K.S., E.M.v.L., E.D.K., A.M.S., W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Department of Oncological Sciences (W.J.M.M.), Icahn School of Medicine at Mount Sinai, New York, NY.,Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, the Netherlands (M.M.T.v.L., M.L.S., W.J.M.M.).,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, the Netherlands (W.J.M.M.)
| |
Collapse
|
11
|
Sofias AM, Toner YC, Meerwaldt AE, van Leent MMT, Soultanidis G, Elschot M, Gonai H, Grendstad K, Flobak Å, Neckmann U, Wolowczyk C, Fisher EL, Reiner T, Davies CDL, Bjørkøy G, Teunissen AJP, Ochando J, Pérez-Medina C, Mulder WJM, Hak S. Tumor Targeting by α vβ 3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking. ACS Nano 2020; 14:7832-7846. [PMID: 32413260 PMCID: PMC7392528 DOI: 10.1021/acsnano.9b08693] [Citation(s) in RCA: 61] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles' (NP) in vivo behavior is complex and the immune system's role in their application remains elusive. At present, only passive-targeting nanoformulations have been clinically approved, while more complicated active-targeting strategies typically fail to advance from the early clinical phase stage. This absence of clinical translation is, among others, due to the very limited understanding for in vivo targeting mechanisms. Dynamic in vivo phenomena such as NPs' real-time targeting kinetics and phagocytes' contribution to active NP targeting remain largely unexplored. To better understand in vivo targeting, monitoring NP accumulation and distribution at complementary levels of spatial and temporal resolution is imperative. Here, we integrate in vivo positron emission tomography/computed tomography imaging with intravital microscopy and flow cytometric analyses to study αvβ3-integrin-targeted cyclic arginine-glycine-aspartate decorated liposomes and oil-in-water nanoemulsions in tumor mouse models. We observed that ligand-mediated accumulation in cancerous lesions is multifaceted and identified "NP hitchhiking" with phagocytes to contribute considerably to this intricate process. We anticipate that this understanding can facilitate rational improvement of nanomedicine applications and that immune cell-NP interactions can be harnessed to develop clinically viable nanomedicine-based immunotherapies.
Collapse
Affiliation(s)
- Alexandros Marios Sofias
- Department
of Circulation and Medical Imaging, Faculty of Medicine and Health
Sciences, Norwegian University of Science
and Technology (NTNU), 7030 Trondheim, Norway
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
- Department
of Nanomedicine and Theranostics, Institute for Experimental Molecular
Imaging, Faculty of Medicine, RWTH Aachen
University, 52074 Aachen, Germany
- or
| | - Yohana C. Toner
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Anu E. Meerwaldt
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
- Biomedical
MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht and Utrecht University, 3584 CX Utrecht, The Netherlands
| | - Mandy M. T. van Leent
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
- Department
of Medical Biochemistry, Amsterdam University
Medical Centers, 1105 AZ Amsterdam, The Netherlands
| | - Georgios Soultanidis
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Mattijs Elschot
- Department
of Circulation and Medical Imaging, Faculty of Medicine and Health
Sciences, Norwegian University of Science
and Technology (NTNU), 7030 Trondheim, Norway
- Department
of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, 7030 Trondheim, Norway
| | - Haruki Gonai
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Kristin Grendstad
- Department
of Physics, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), 7034 Trondheim, Norway
| | - Åsmund Flobak
- The
Cancer Clinic, St. Olav’s University
Hospital, 7030 Trondheim, Norway
- Department
of Clinical and Molecular Medicine, Faculty of Medicine and Health
Sciences, Norwegian University of Science
and Technology (NTNU), 7030 Trondheim, Norway
| | - Ulrike Neckmann
- Department
of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway
- Centre
of Molecular Inflammation Research (CEMIR), Faculty of Medicine and
Health Sciences, Norwegian University of
Science and Technology (NTNU), 7030 Trondheim, Norway
| | - Camilla Wolowczyk
- Department
of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway
- Centre
of Molecular Inflammation Research (CEMIR), Faculty of Medicine and
Health Sciences, Norwegian University of
Science and Technology (NTNU), 7030 Trondheim, Norway
| | - Elizabeth L. Fisher
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Thomas Reiner
- Department
of Radiology, Memorial Sloan Kettering Cancer
Center, New York, New York 10065, United States
- Department
of Radiology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Catharina de Lange Davies
- Department
of Physics, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), 7034 Trondheim, Norway
| | - Geir Bjørkøy
- Department
of Clinical and Molecular Medicine, Faculty of Medicine and Health
Sciences, Norwegian University of Science
and Technology (NTNU), 7030 Trondheim, Norway
- Department
of Biomedical Laboratory Science, Faculty of Natural Sciences, Norwegian University of Science and Technology (NTNU), 7030 Trondheim, Norway
- Centre
of Molecular Inflammation Research (CEMIR), Faculty of Medicine and
Health Sciences, Norwegian University of
Science and Technology (NTNU), 7030 Trondheim, Norway
| | - Abraham J. P. Teunissen
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Jordi Ochando
- Department
of Oncological Sciences, Icahn School of
Medicine at Mount Sinai, New York, New York 10029, United States
- Transplant
Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, 28220 Madrid, Spain
| | - Carlos Pérez-Medina
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
- Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029 Madrid, Spain
| | - Willem J. M. Mulder
- BioMedical
Engineering and Imaging Institute, Icahn
School of Medicine at Mount Sinai, New York, New York 10029, United States
- Department
of Medical Biochemistry, Amsterdam University
Medical Centers, 1105 AZ Amsterdam, The Netherlands
- Laboratory
of Chemical Biology, Department of Biochemical Engineering, Eindhoven University of Technology, 5612 AP Eindhoven, The Netherlands
| | - Sjoerd Hak
- Department
of Circulation and Medical Imaging, Faculty of Medicine and Health
Sciences, Norwegian University of Science
and Technology (NTNU), 7030 Trondheim, Norway
- Department
of Biotechnology and Nanomedicine, SINTEF
Industry, 7034 Trondheim, Norway
- or
| |
Collapse
|
12
|
Senders ML, Meerwaldt AE, van Leent MMT, Sanchez-Gaytan BL, van de Voort JC, Toner YC, Maier A, Klein ED, Sullivan NAT, Sofias AM, Groenen H, Faries C, Oosterwijk RS, van Leeuwen EM, Fay F, Chepurko E, Reiner T, Duivenvoorden R, Zangi L, Dijkhuizen RM, Hak S, Swirski FK, Nahrendorf M, Pérez-Medina C, Teunissen AJP, Fayad ZA, Calcagno C, Strijkers GJ, Mulder WJM. Probing myeloid cell dynamics in ischaemic heart disease by nanotracer hot-spot imaging. Nat Nanotechnol 2020; 15:398-405. [PMID: 32313216 PMCID: PMC7416336 DOI: 10.1038/s41565-020-0642-4] [Citation(s) in RCA: 37] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2018] [Accepted: 01/16/2020] [Indexed: 05/19/2023]
Abstract
Ischaemic heart disease evokes a complex immune response. However, tools to track the systemic behaviour and dynamics of leukocytes non-invasively in vivo are lacking. Here, we present a multimodal hot-spot imaging approach using an innovative high-density lipoprotein-derived nanotracer with a perfluoro-crown ether payload (19F-HDL) to allow myeloid cell tracking by 19F magnetic resonance imaging. The 19F-HDL nanotracer can additionally be labelled with zirconium-89 and fluorophores to detect myeloid cells by in vivo positron emission tomography imaging and optical modalities, respectively. Using our nanotracer in atherosclerotic mice with myocardial infarction, we observed rapid myeloid cell egress from the spleen and bone marrow by in vivo 19F-HDL magnetic resonance imaging. Concurrently, using ex vivo techniques, we showed that circulating pro-inflammatory myeloid cells accumulated in atherosclerotic plaques and at the myocardial infarct site. Our multimodality imaging approach is a valuable addition to the immunology toolbox, enabling the study of complex myeloid cell behaviour dynamically.
Collapse
Affiliation(s)
- Max L Senders
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
| | - Anu E Meerwaldt
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht/Utrecht University, Utrecht, the Netherlands
| | - Mandy M T van Leent
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
| | - Brenda L Sanchez-Gaytan
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Instituto de Ciencias ICUAP, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
| | - Jan C van de Voort
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yohana C Toner
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alexander Maier
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emma D Klein
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Nathaniel A T Sullivan
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alexandros Marios Sofias
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
| | - Hannah Groenen
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christopher Faries
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Roderick S Oosterwijk
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther M van Leeuwen
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Francois Fay
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Institut Galien Paris Sud, Faculté de Pharmacie, CNRS, Université Paris-Sud, Université Paris-Saclay, Paris, France
| | - Elena Chepurko
- Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
| | - Raphael Duivenvoorden
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Lior Zangi
- Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Rick M Dijkhuizen
- Biomedical MR Imaging and Spectroscopy Group, Center for Image Sciences, University Medical Center Utrecht/Utrecht University, Utrecht, the Netherlands
| | - Sjoerd Hak
- Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
| | - Filip K Swirski
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Carlos Pérez-Medina
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Abraham J P Teunissen
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Zahi A Fayad
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Claudia Calcagno
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Gustav J Strijkers
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Biomedical Engineering and Physics, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
| | - Willem J M Mulder
- BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
| |
Collapse
|
13
|
Calcagno C, Pérez-Medina C, Mulder WJM, Fayad ZA. Whole-Body Atherosclerosis Imaging by Positron Emission Tomography/Magnetic Resonance Imaging: From Mice to Nonhuman Primates. Arterioscler Thromb Vasc Biol 2020; 40:1123-1134. [PMID: 32237905 DOI: 10.1161/atvbaha.119.313629] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Cardiovascular disease due to atherosclerosis is still the main cause of morbidity and mortality worldwide. This disease is a complex systemic disorder arising from a network of pathological processes within the arterial vessel wall, and, outside of the vasculature, in the hematopoietic system and organs involved in metabolism. Recent years have seen tremendous efforts in the development and validation of quantitative imaging technologies for the noninvasive evaluation of patients with atherosclerotic cardiovascular disease. Specifically, the advent of combined positron emission tomography and magnetic resonance imaging scanners has opened new exciting opportunities in cardiovascular imaging. In this review, we will describe how combined positron emission tomography/magnetic resonance imaging scanners can be leveraged to evaluate atherosclerotic cardiovascular disease at the whole-body level, with specific focus on preclinical animal models of disease, from mouse to nonhuman primates. We will broadly describe 3 major areas of application: (1) vascular imaging, for advanced atherosclerotic plaque phenotyping and evaluation of novel imaging tracers or therapeutic interventions; (2) assessment of the ischemic heart and brain; and (3) whole-body imaging of the hematopoietic system. Finally, we will provide insights on potential novel technical developments which may further increase the relevance of integrated positron emission tomography/magnetic resonance imaging in preclinical atherosclerosis studies.
Collapse
Affiliation(s)
- Claudia Calcagno
- From the BioMedical Engineering and Imaging Institute (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Department of Radiology (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY
| | - Carlos Pérez-Medina
- From the BioMedical Engineering and Imaging Institute (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Department of Radiology (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.P.-M.)
| | - Willem J M Mulder
- From the BioMedical Engineering and Imaging Institute (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Department of Radiology (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Department of Oncological Sciences (W.J.M.M.), Icahn School of Medicine at Mount Sinai, NY.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, the Netherlands (W.J.M.M.)
| | - Zahi A Fayad
- From the BioMedical Engineering and Imaging Institute (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY.,Department of Radiology (C.C., C.P.-M., W.J.M.M., Z.A.F.), Icahn School of Medicine at Mount Sinai, NY
| |
Collapse
|
14
|
Abstract
The immune system's role in atherosclerosis has long been an important research topic and is increasingly investigated for therapeutic and diagnostic purposes. Therefore, noninvasive imaging of hematopoietic organs and immune cells will undoubtedly improve atherosclerosis phenotyping and serve as a monitoring method for immunotherapeutic treatments. Among the available imaging techniques, positron emission tomography's unique features make it an ideal tool to quantitatively image the immune response in the context of atherosclerosis and afford reliable readouts to guide medical interventions in cardiovascular disease. Here, we summarize the state of the art in the field of atherosclerosis positron emission tomography immunoimaging and provide an outlook on current and future applications.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- From the Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.P.-M.).,Icahn School of Medicine at Mount Sinai, New York (C.P.-M., Z.A.F., W.J.M.M.)
| | - Zahi A Fayad
- Icahn School of Medicine at Mount Sinai, New York (C.P.-M., Z.A.F., W.J.M.M.)
| | - Willem J M Mulder
- Icahn School of Medicine at Mount Sinai, New York (C.P.-M., Z.A.F., W.J.M.M.).,Eindhoven University of Technology, the Netherlands (W.J.M.M.)
| |
Collapse
|
15
|
Pérez-Medina C, Teunissen AJ, Kluza E, Mulder WJ, van der Meel R. Nuclear imaging approaches facilitating nanomedicine translation. Adv Drug Deliv Rev 2020; 154-155:123-141. [PMID: 32721459 DOI: 10.1016/j.addr.2020.07.017] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Revised: 07/08/2020] [Accepted: 07/17/2020] [Indexed: 02/07/2023]
Abstract
Nanomedicine approaches can effectively modulate the biodistribution and bioavailability of therapeutic agents, improving their therapeutic index. However, despite the ever-increasing amount of literature reporting on preclinical nanomedicine, the number of nanotherapeutics receiving FDA approval remains relatively low. Several barriers exist that hamper the effective preclinical evaluation and clinical translation of nanotherapeutics. Key barriers include insufficient understanding of nanomedicines' in vivo behavior, inadequate translation from murine models to larger animals, and a lack of patient stratification strategies. Integrating quantitative non-invasive imaging techniques in nanomedicine development offers attractive possibilities to address these issues. Among the available imaging techniques, nuclear imaging by positron emission tomography (PET) and single-photon emission computed tomography (SPECT) are highly attractive in this context owing to their quantitative nature and uncontested sensitivity. In basic and translational research, nuclear imaging techniques can provide critical quantitative information about pharmacokinetic parameters, biodistribution profiles or target site accumulation of nanocarriers and their associated payload. During clinical evaluation, nuclear imaging can be used to select patients amenable to nanomedicine treatment. Here, we review how nuclear imaging-based approaches are increasingly being integrated into nanomedicine development and discuss future developments that will accelerate their clinical translation.
Collapse
|
16
|
Binderup T, Duivenvoorden R, Fay F, van Leent MMT, Malkus J, Baxter S, Ishino S, Zhao Y, Sanchez-Gaytan B, Teunissen AJP, Frederico YCA, Tang J, Carlucci G, Lyashchenko S, Calcagno C, Karakatsanis N, Soultanidis G, Senders ML, Robson PM, Mani V, Ramachandran S, Lobatto ME, Hutten BA, Granada JF, Reiner T, Swirski FK, Nahrendorf M, Kjaer A, Fisher EA, Fayad ZA, Pérez-Medina C, Mulder WJM. Imaging-assisted nanoimmunotherapy for atherosclerosis in multiple species. Sci Transl Med 2019; 11:eaaw7736. [PMID: 31434756 PMCID: PMC7328283 DOI: 10.1126/scitranslmed.aaw7736] [Citation(s) in RCA: 40] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Accepted: 07/09/2019] [Indexed: 01/01/2023]
Abstract
Nanomedicine research produces hundreds of studies every year, yet very few formulations have been approved for clinical use. This is due in part to a reliance on murine studies, which have limited value in accurately predicting translational efficacy in larger animal models and humans. Here, we report the scale-up of a nanoimmunotherapy from mouse to large rabbit and porcine atherosclerosis models, with an emphasis on the solutions we implemented to overcome production and evaluation challenges. Specifically, we integrated translational imaging readouts within our workflow to both analyze the nanoimmunotherapeutic's in vivo behavior and assess treatment response in larger animals. We observed our nanoimmunotherapeutic's anti-inflammatory efficacy in mice, as well as rabbits and pigs. Nanoimmunotherapy-mediated reduction of inflammation in the large animal models halted plaque progression, supporting the approach's translatability and potential to acutely treat atherosclerosis.
Collapse
Affiliation(s)
- Tina Binderup
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark
| | - Raphaël Duivenvoorden
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Nephrology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 XZ Nijmegen, Netherlands
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Institut Galien Paris Sud, Faculté de Pharmacie, CNRS, Univ. Paris-Sud, Université Paris-Saclay, 92290 Châtenay-Malabry, France
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Joost Malkus
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Samantha Baxter
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Seigo Ishino
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Brenda Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Abraham J P Teunissen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yohana C A Frederico
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jun Tang
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Giuseppe Carlucci
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Bernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, NY 10016, USA
| | - Serge Lyashchenko
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Nicolas Karakatsanis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Georgios Soultanidis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, Netherlands
| | - Philip M Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Venkatesh Mani
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mark E Lobatto
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Radiology, Spaarne Gasthuis, 2035 RC Haarlem, Netherlands
| | - Barbara A Hutten
- Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers, 1105 AZ Amsterdam, Netherlands
| | - Juan F Granada
- CRF Skirball Center for Innovation, Cardiovascular Research Foundation, Orangeburg, NY 10962, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Filip K Swirski
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Matthias Nahrendorf
- Center for Systems Biology and Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine and PET and Cluster for Molecular Imaging, Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark
| | - Edward A Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, NY 10016, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Centro Nacional de Investigaciones Cardiovasculares Carlos III, 28029 Madrid, Spain
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Medical Biochemistry, Amsterdam University Medical Centers, University of Amsterdam, 1105 AZ Amsterdam, Netherlands
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, 5612 AZ Eindhoven, Netherlands
| |
Collapse
|
17
|
Mason CA, Kossatz S, Carter LM, Pirovano G, Brand C, Guru N, Pérez-Medina C, Lewis JS, Mulder WJM, Reiner T. An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. J Nucl Med 2019; 61:433-436. [PMID: 31420495 PMCID: PMC7067531 DOI: 10.2967/jnumed.119.230466] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Accepted: 07/24/2019] [Indexed: 12/11/2022] Open
Abstract
The immune function within the tumor microenvironment has become a prominent therapeutic target, with tumor-associated macrophages (TAMs) playing a critical role in immune suppression. We propose an 89Zr-labeled high-density lipoprotein (89Zr-HDL) nanotracer as a means of monitoring response to immunotherapy. Methods: Female MMTV-PyMT mice were treated with pexidartinib, a colony-stimulating factor 1 receptor (CSF1R) inhibitor, to reduce TAM density. The accumulation of 89Zr-HDL within the tumor was assessed using PET/CT imaging and autoradiography, whereas TAM burden was determined using immunofluorescence. Results: A significant reduction in 89Zr-HDL accumulation was observed in PET/CT images, with 2.9% ± 0.3% and 3.7% ± 0.2% injected dose/g for the pexidartinib- and vehicle-treated mice, respectively. This reduction was corroborated ex vivo and correlated with decreased TAM density. Conclusion: These results support the potential use of 89Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhibitors and other therapeutic strategies targeting TAMs.
Collapse
Affiliation(s)
- Christian A Mason
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Susanne Kossatz
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Lukas M Carter
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Giacomo Pirovano
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Christian Brand
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Navjot Guru
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.,Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.,Department of Radiology, Weill Cornell Medical College, New York, New York
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.,Department of Medical Biochemistry, Amsterdam University Medical Centers, Academic Medical Center, Amsterdam, The Netherlands
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York .,Department of Radiology, Weill Cornell Medical College, New York, New York.,Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, New York; and.,Center for Molecular Imaging and Nanotechnology (CMINT), Memorial Sloan Kettering Cancer Center, New York, New York
| |
Collapse
|
18
|
Lobatto ME, Binderup T, Robson PM, Giesen LFP, Calcagno C, Witjes J, Fay F, Baxter S, Wessel CH, Eldib M, Bini J, Carlin SD, Stroes ESG, Storm G, Kjaer A, Lewis JS, Reiner T, Fayad ZA, Mulder WJM, Pérez-Medina C. Multimodal Positron Emission Tomography Imaging to Quantify Uptake of 89Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjug Chem 2019; 31:360-368. [PMID: 31095372 DOI: 10.1021/acs.bioconjchem.9b00256] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Nanotherapy has recently emerged as an experimental treatment option for atherosclerosis. To fulfill its promise, robust noninvasive imaging approaches for subject selection and treatment evaluation are warranted. To that end, we present here a positron emission tomography (PET)-based method for quantification of liposomal nanoparticle uptake in the atherosclerotic vessel wall. We evaluated a modular procedure to label liposomal nanoparticles with the radioisotope zirconium-89 (89Zr). Their biodistribution and vessel wall targeting in a rabbit atherosclerosis model was evaluated up to 15 days after intravenous injection by PET/computed tomography (CT) and PET/magnetic resonance imaging (PET/MRI). Vascular permeability was assessed in vivo using three-dimensional dynamic contrast-enhanced MRI (3D DCE-MRI) and ex vivo using near-infrared fluorescence (NIRF) imaging. The 89Zr-radiolabeled liposomes displayed a biodistribution pattern typical of long-circulating nanoparticles. Importantly, they markedly accumulated in atherosclerotic lesions in the abdominal aorta, as evident on PET/MRI and confirmed by autoradiography, and this uptake moderately correlated with vascular permeability. The method presented herein facilitates the development of nanotherapy for atherosclerotic disease as it provides a tool to screen for nanoparticle targeting in individual subjects' plaques.
Collapse
Affiliation(s)
- Mark E Lobatto
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Department of Radiology , Spaarne Gasthuis , 2035 RC Haarlem , The Netherlands
| | - Tina Binderup
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging , Rigshospitalet & University of Copenhagen , 2100 Copenhagen , Denmark
| | - Philip M Robson
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Luuk F P Giesen
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Julia Witjes
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Francois Fay
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Institut Galien Paris Sud UMR 8612, Faculté de Pharmacie, CNRS, Univ. Paris-Sud Université Paris-Saclay , 92290 Châtenay-Malabry , France
| | - Samantha Baxter
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Chang Ho Wessel
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Mootaz Eldib
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Jason Bini
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Sean D Carlin
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Erik S G Stroes
- Department of Vascular Medicine , Academic Medical Center , 1105 AZ Amsterdam , The Netherlands
| | - Gert Storm
- Department of Targeted Therapeutics, MIRA Institute , University of Twente , 7522 NB Enschede , The Netherlands.,Utrecht Institute for Pharmaceutical Sciences , Utrecht University , 3512 JE Utrecht , The Netherlands
| | - Andreas Kjaer
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging , Rigshospitalet & University of Copenhagen , 2100 Copenhagen , Denmark
| | - Jason S Lewis
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.,Program in Molecular Pharmacology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Thomas Reiner
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.,Chemical Biology Program , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Eindhoven University of Technology , 5612 AZ Eindhoven , The Netherlands.,Department of Oncological Sciences , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Centro Nacional de Investigaciones Cardiovasculares Carlos III , 28029 Madrid , Spain
| |
Collapse
|
19
|
Abstract
Atherosclerosis is a chronic disease of the large arteries and the underlying cause of myocardial infarction and stroke. Atherosclerosis is driven by cholesterol accumulation and subsequent inflammation in the vessel wall. Despite the clinical successes of lipid-lowering treatments, atherosclerosis remains one of the major threats to human health worldwide. Over the past 20 years, insights into cardiovascular immunopathology have provided a plethora of new potential therapeutic targets to reduce the risk of atherosclerosis and have shifted the therapeutic focus from lipids to inflammation. In 2017, the CANTOS trial demonstrated for the first time the beneficial effects of targeting inflammation to treat cardiovascular disease by showing that IL-1β inhibition can reduce the recurrence rate of cardiovascular events in a large cohort of patients. At the same time, preclinical studies have highlighted nanotechnology approaches that facilitate the specific targeting of innate immune cells, which could potentially generate more effective immunomodulatory treatments to induce disease regression and prevent the recurrence of cardiovascular events. The clinical translation of such nanoimmunotherapies and their application to treat patients with ischaemic heart disease are challenges that lie ahead.
Collapse
Affiliation(s)
- Raphaël Duivenvoorden
- Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center, location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
- Department of Internal Medicine, Section of Nephrology, Amsterdam University Medical Centers, location Academic Medical Cente, University of Amsterdam, Amsterdam, Netherlands.
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Medical Biochemistry, Amsterdam University Medical Centers, location Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
- Department of Oncological Sciences, The Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands.
| |
Collapse
|
20
|
Braza MS, van Leent MMT, Lameijer M, Sanchez-Gaytan BL, Arts RJW, Pérez-Medina C, Conde P, Garcia MR, Gonzalez-Perez M, Brahmachary M, Fay F, Kluza E, Kossatz S, Dress RJ, Salem F, Rialdi A, Reiner T, Boros P, Strijkers GJ, Calcagno CC, Ginhoux F, Marazzi I, Lutgens E, Nicolaes GAF, Weber C, Swirski FK, Nahrendorf M, Fisher EA, Duivenvoorden R, Fayad ZA, Netea MG, Mulder WJM, Ochando J. Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance. Immunity 2018; 49:819-828.e6. [PMID: 30413362 PMCID: PMC6251711 DOI: 10.1016/j.immuni.2018.09.008] [Citation(s) in RCA: 139] [Impact Index Per Article: 23.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Revised: 07/03/2018] [Accepted: 09/10/2018] [Indexed: 12/11/2022]
Abstract
Inducing graft acceptance without chronic immunosuppression remains an elusive goal in organ transplantation. Using an experimental transplantation mouse model, we demonstrate that local macrophage activation through dectin-1 and toll-like receptor 4 (TLR4) drives trained immunity-associated cytokine production during allograft rejection. We conducted nanoimmunotherapeutic studies and found that a short-term mTOR-specific high-density lipoprotein (HDL) nanobiologic treatment (mTORi-HDL) averted macrophage aerobic glycolysis and the epigenetic modifications underlying inflammatory cytokine production. The resulting regulatory macrophages prevented alloreactive CD8+ T cell-mediated immunity and promoted tolerogenic CD4+ regulatory T (Treg) cell expansion. To enhance therapeutic efficacy, we complemented the mTORi-HDL treatment with a CD40-TRAF6-specific nanobiologic (TRAF6i-HDL) that inhibits co-stimulation. This synergistic nanoimmunotherapy resulted in indefinite allograft survival. Together, we show that HDL-based nanoimmunotherapy can be employed to control macrophage function in vivo. Our strategy, focused on preventing inflammatory innate immune responses, provides a framework for developing targeted therapies that promote immunological tolerance.
Collapse
Affiliation(s)
- Mounia S Braza
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Marnix Lameijer
- Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
| | - Brenda L Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Rob J W Arts
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Patricia Conde
- Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Mercedes R Garcia
- Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Maria Gonzalez-Perez
- Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | - Manisha Brahmachary
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Francois Fay
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ewelina Kluza
- Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands
| | - Susanne Kossatz
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Regine J Dress
- Singapore Immunology Network (SIgN), A STAR, Singapore, Singapore
| | - Fadi Salem
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alexander Rialdi
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, New York, NY, USA
| | - Peter Boros
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Gustav J Strijkers
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Biomedical Engineering and Physics, Academic Medical Center, Amsterdam, the Netherlands
| | - Claudia C Calcagno
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Florent Ginhoux
- Singapore Immunology Network (SIgN), A STAR, Singapore, Singapore
| | - Ivan Marazzi
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther Lutgens
- Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Institute for Cardiovascular Prevention, Ludwig-Maximilians University Munich, Munich, Germany
| | - Gerry A F Nicolaes
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands
| | - Christian Weber
- Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, the Netherlands
| | - Filip K Swirski
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
| | - Edward A Fisher
- Department of Medicine (Cardiology), New York University School of Medicine, New York, NY, USA
| | - Raphaël Duivenvoorden
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Nephrology, Academic Medical Center, Amsterdam, the Netherlands; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Mihai G Netea
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands; Department for Genomics & Immunoregulation, Life and Medical Sciences Institute (LIMES), University of Bonn, Bonn, Germany
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, the Netherlands.
| | - Jordi Ochando
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Transplant Immunology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
| |
Collapse
|
21
|
Srimathveeravalli G, Abdel-Atti D, Pérez-Medina C, Takaki H, Solomon SB, Mulder WJM, Reiner T. Reversible Electroporation-Mediated Liposomal Doxorubicin Delivery to Tumors Can Be Monitored With 89Zr-Labeled Reporter Nanoparticles. Mol Imaging 2018; 17:1536012117749726. [PMID: 29480077 PMCID: PMC5833236 DOI: 10.1177/1536012117749726] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Reversible electroporation (RE) can facilitate nanoparticle delivery to tumors through direct transfection and from changes in vascular permeability. We investigated a radiolabeled liposomal nanoparticle (89Zr-NRep) for monitoring RE-mediated liposomal doxorubicin (DOX) delivery in mouse tumors. Intravenously delivered 89Zr-NRep allowed positron emission tomography imaging of electroporation-mediated nanoparticle uptake. The relative order of 89Zr-NRep injection and electroporation did not result in significantly different overall tumor uptake, suggesting direct transfection and vascular permeability can independently mediate deposition of 89Zr-NRep in tumors. 89Zr-NRep and DOX uptake correlated well in both electroporated and control tumors at all experimental time points. Electroporation accelerated 89Zr-NRep and DOX deposition into tumors and increased DOX dosing. Reversible electroporation–related vascular effects seem to play an important role in nanoparticle delivery to tumors and drug uptake can be quantified with 89Zr-NRep.
Collapse
Affiliation(s)
- Govindarajan Srimathveeravalli
- 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,2 Department of Radiology, Weill-Cornell Medical College, New York, NY, USA
| | - Dalya Abdel-Atti
- 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Carlos Pérez-Medina
- 3 Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Haruyuki Takaki
- 4 Department of Radiology, Hyogo College of Medicine, Hyogo, Japan
| | - Stephen B Solomon
- 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,2 Department of Radiology, Weill-Cornell Medical College, New York, NY, USA
| | - Willem J M Mulder
- 3 Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,5 Department of Medical Biochemistry, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Thomas Reiner
- 1 Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.,2 Department of Radiology, Weill-Cornell Medical College, New York, NY, USA
| |
Collapse
|
22
|
Gonzales J, Kossatz S, Roberts S, Pirovano G, Brand C, Pérez-Medina C, Donabedian P, de la Cruz MJ, Mulder WJM, Reiner T. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer. Bioconjug Chem 2018; 29:3776-3782. [PMID: 30354077 DOI: 10.1021/acs.bioconjchem.8b00640] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The preclinical potential of many diagnostic and therapeutic small molecules is limited by their rapid washout kinetics and consequently modest pharmacological performances. In several cases, these could be improved by loading the small molecules into nanoparticulates, improving blood half-life, in vivo uptake and overall pharmacodynamics. In this study, we report a nanoemulsion (NE) encapsulated form of PARPi-FL. As a proof of concept, we used PARPi-FL, which is a fluorescently labeled sensor for olaparib, a FDA-approved small molecule inhibitor of the nuclear enzyme poly(ADP-ribose)polymerase 1 (PARP1). Encapsulated PARPi-FL showed increased blood half-life, and delineated subcutaneous xenografts of small cell lung cancer (SCLC), a fast-progressing disease where efficient treatment options remain an unmet clinical need. Our study demonstrates an effective method for expanding the circulation time of a fluorescent PARP inhibitor, highlighting the pharmacokinetic benefits of nanoemulsions as nanocarriers and confirming the value of PARPi-FL as an imaging agent targeting PARP1 in small cell lung cancer.
Collapse
Affiliation(s)
- Junior Gonzales
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Susanne Kossatz
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Sheryl Roberts
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Giacomo Pirovano
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Christian Brand
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Department of Radiology , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States
| | - Patrick Donabedian
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - M Jason de la Cruz
- Structural Biology Program, Sloan Kettering Institute , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Department of Radiology , Icahn School of Medicine at Mount Sinai , New York , New York 10029 , United States.,Laboratory of Chemical Biology, Department of Biomedical Engineering and Institute for Complex Molecular Systems , Eindhoven University of Technology , Eindhoven , The Netherlands
| | - Thomas Reiner
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , United States.,Department of Radiology , Weill Cornell Medical College , New York , New York 10065 , United States
| |
Collapse
|
23
|
Senders ML, Hernot S, Carlucci G, van de Voort JC, Fay F, Calcagno C, Tang J, Alaarg A, Zhao Y, Ishino S, Palmisano A, Boeykens G, Meerwaldt AE, Sanchez-Gaytan BL, Baxter S, Zendman L, Lobatto ME, Karakatsanis NA, Robson PM, Broisat A, Raes G, Lewis JS, Tsimikas S, Reiner T, Fayad ZA, Devoogdt N, Mulder WJM, Pérez-Medina C. Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging 2018; 12:2015-2026. [PMID: 30343086 PMCID: PMC6461528 DOI: 10.1016/j.jcmg.2018.07.027] [Citation(s) in RCA: 49] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Revised: 06/11/2018] [Accepted: 07/12/2018] [Indexed: 12/13/2022]
Abstract
OBJECTIVES This study sought to develop an integrative positron emission tomography (PET) with magnetic resonance imaging (MRI) procedure for accurate atherosclerotic plaque phenotyping, facilitated by clinically approved and nanobody radiotracers. BACKGROUND Noninvasive characterization of atherosclerosis remains a challenge in clinical practice. The limitations of current diagnostic methods demonstrate that, in addition to atherosclerotic plaque morphology and composition, disease activity needs to be evaluated. METHODS We screened 3 nanobody radiotracers targeted to different biomarkers of atherosclerosis progression, namely vascular cell adhesion molecule (VCAM)-1, lectin-like oxidized low-density lipoprotein receptor (LOX)-1, and macrophage mannose receptor (MMR). The nanobodies, initially radiolabeled with copper-64 (64Cu), were extensively evaluated in Apoe–/– mice and atherosclerotic rabbits using a combination of in vivo PET/MRI readouts and ex vivo radioactivity counting, autoradiography, and histological analyses. RESULTS The 3 nanobody radiotracers accumulated in atherosclerotic plaques and displayed short circulation times due to fast renal clearance. The MMR nanobody was selected for labeling with gallium-68 (68Ga), a short-lived radioisotope with high clinical relevance, and used in an ensuing atherosclerosis progression PET/MRI study. Macrophage burden was longitudinally studied by 68Ga-MMR–PET, plaque burden by T2-weighted MRI, and neovascularization by dynamic contrast-enhanced (DCE) MRI. Additionally, inflammation and microcalcifications were evaluated by fluorine-18 (18F)-labeled fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (18F-NaF) PET, respectively. We observed an increase in all the aforementioned measures as disease progressed, and the imaging signatures correlated with histopathological features. CONCLUSIONS We have evaluated nanobody-based radiotracers in rabbits and developed an integrative PET/MRI protocol that allows noninvasive assessment of different processes relevant to atherosclerosis progression. This approach allows the multiparametric study of atherosclerosis and can aid in early stage anti-atherosclerosis drug trials.
Collapse
Affiliation(s)
- Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands
| | - Sophie Hernot
- In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium
| | - Giuseppe Carlucci
- Bernard and Irene Schwarz Center for Biomedical Imaging, New York University, New York, New York; Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Jan C van de Voort
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Chemistry, York College of The City University of New York, New York, New York
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Jun Tang
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Amr Alaarg
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Biomaterials Science and Technology, Technical Medical Centre. University of Twente, Enschede, the Netherlands
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Seigo Ishino
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Anna Palmisano
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Unit of Clinical Research in Radiology, Experimental Imaging Center, San Raffaele Scientific Institute, Milan, Italy
| | - Gilles Boeykens
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Anu E Meerwaldt
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Brenda L Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Samantha Baxter
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Laura Zendman
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Mark E Lobatto
- Department of Radiology, Academic Medical Center, Amsterdam, the Netherlands
| | - Nicolas A Karakatsanis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Philip M Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Alexis Broisat
- Bioclinic Radiopharmaceutics Laboratory, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche S 1039, Grenoble, France
| | - Geert Raes
- Research Group of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium; Laboratory of Myeloid Cell Immunology, Vlaams Instituut voor Biotechnologie Inflammation Research Center, Ghent, Belgium
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Weill Cornell Medical College, New York, New York; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Sotirios Tsimikas
- Division of Cardiovascular Diseases, Sulpizio Cardiovascular Center, Department of Medicine, University of California-La Jolla, San Diego, California
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Radiology, Weill Cornell Medical College, New York, New York
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Nick Devoogdt
- In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel, Brussels, Belgium
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands.
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
| |
Collapse
|
24
|
Abstract
Supramolecular systems have applications in areas as diverse as materials science, biochemistry, analytical chemistry, and nanomedicine. However, analyzing such systems can be challenging due to the wide range of time scales, binding strengths, distances, and concentrations at which non-covalent phenomena take place. Due to their versatility and sensitivity, Förster resonance energy transfer (FRET)-based techniques are excellently suited to meet such challenges. Here, we detail the ways in which FRET has been used to study non-covalent interactions in both synthetic and biological supramolecular systems. Among other topics, we examine methods to measure molecular forces, determine protein conformations, monitor assembly kinetics, and visualize in vivo drug release from nanoparticles. Furthermore, we highlight multiplex FRET techniques, discuss the field's limitations, and provide a perspective on new developments.
Collapse
Affiliation(s)
- Abraham J. P. Teunissen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029, USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029, USA
| | - Andries Meijerink
- Department of Chemistry, Utrecht University, Princetonplein 1, 3584 CC Utrecht, The Netherlands
| | - Willem J. M. Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, 1470 Madison Avenue, New York, NY 10029, USA
- Department of Medical Biochemistry, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
- Laboratory of Chemical biology, Department of Biomedical Engineering and Institute for Complex Molecular systems, Eindhoven University of Technology, P.O. Box 513, 5600 MB, The Netherlands
| |
Collapse
|
25
|
Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TTP, Kroon J, Stroes ESG, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Calcagno C, Fisher EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, Duivenvoorden R. Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat Biomed Eng 2018; 2:623. [PMID: 31015637 DOI: 10.1038/s41551-018-0281-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
In the version of this Article originally published, the surname of the author Edward A. Fisher was spelt incorrectly as 'Fischer'. This has now been corrected.
Collapse
Affiliation(s)
- Marnix Lameijer
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Tina Binderup
- Cluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Joost Malkus
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Brenda L Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Abraham J P Teunissen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Nicolas Karakatsanis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Philip Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Xianxiao Zhou
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yuxiang Ye
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Gregory Wojtkiewicz
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Tom T P Seijkens
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Jeffrey Kroon
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands
| | - Erik S G Stroes
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands
| | - Andreas Kjaer
- Cluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Jordi Ochando
- Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Edward A Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY, USA
| | - Bin Zhang
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ryan E Temel
- Saha Cardiovascular Research Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA
| | - Filip K Swirski
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther Lutgens
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig-Maximilians University, Munich, Germany
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands.
| | - Raphaël Duivenvoorden
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands.
- Department of Nephrology, Academic Medical Center, Amsterdam, The Netherlands.
| |
Collapse
|
26
|
Roberts S, Andreou C, Choi C, Donabedian P, Jayaraman M, Pratt EC, Tang J, Pérez-Medina C, Jason de la Cruz M, Mulder WJM, Grimm J, Kircher M, Reiner T. Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Chem Sci 2018; 9:5646-5657. [PMID: 30061998 PMCID: PMC6049522 DOI: 10.1039/c8sc01706a] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Accepted: 05/14/2018] [Indexed: 12/14/2022] Open
Abstract
Optoacoustic imaging offers the promise of high spatial resolution and, at the same time, penetration depths well beyond the conventional optical imaging technologies, advantages that would be favorable for a variety of clinical applications. However, similar to optical fluorescence imaging, exogenous contrast agents, known as sonophores, need to be developed for molecularly targeted optoacoustic imaging. Despite numerous optoacoustic contrast agents that have been reported, there is a need for more rational design of sonophores. Here, using a library screening approach, we systematically identified and evaluated twelve commercially available near-infrared (690-900 nm) and highly absorbing dyes for multi-spectral optoacoustic tomography (MSOT). In order to achieve more accurate spectral deconvolution and precise data quantification, we sought five practical mathematical methods, namely direct classical least squares based on UV-Vis (UV/Vis-DCLS) or optoacoustic (OA-DCLS) spectra, non-negative LS (NN-LS), independent component analysis (ICA) and principal component analysis (PCA). We found that OA-DCLS is the most suitable method, allowing easy implementation and sufficient accuracy for routine analysis. Here, we demonstrate for the first time that our biocompatible nanoemulsions (NEs), in combination with near-infrared and highly absorbing dyes, enable non-invasive in vivo MSOT detection of tumors. Specifically, we found that NE-IRDye QC1 offers excellent optoacoustic performance and detection compared to related near-infrared NEs. We demonstrate that when loaded with low fluorescent or dark quencher dyes, NEs represent a flexible and new class of exogenous sonophores suitable for non-invasive pre-clinical optoacoustic imaging.
Collapse
Affiliation(s)
- Sheryl Roberts
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
| | - Chrysafis Andreou
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
| | - Crystal Choi
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
| | - Patrick Donabedian
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
| | - Madhumitha Jayaraman
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
| | - Edwin C Pratt
- Department of Molecular Pharmacology , Memorial Sloan Kettering Cancer Center , New York , NY 10054 , USA
| | - Jun Tang
- Cancer Research Institute (CRI) , 29 Broadway , New York , NY 10006 , USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute , Department of Radiology , Mount Sinai School of Medicine , New York , NY 10029 , USA
| | - M Jason de la Cruz
- Structural Biology Program , Sloan Kettering Institute , Memorial Sloan Kettering Cancer Center , New York , New York 10065 , USA
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute , Department of Radiology , Mount Sinai School of Medicine , New York , NY 10029 , USA
- Department of Medical Biochemistry , Academic Medical Center , Amsterdam , The Netherlands
| | - Jan Grimm
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
- Department of Molecular Pharmacology , Memorial Sloan Kettering Cancer Center , New York , NY 10054 , USA
- Department of Radiology , Weill Cornell Medical College , New York , NY 10065 , USA
- Pharmacology Program , Weill Cornell Medical College , New York , NY 10065 , USA
| | - Moritz Kircher
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
- Department of Molecular Pharmacology , Memorial Sloan Kettering Cancer Center , New York , NY 10054 , USA
- Department of Radiology , Weill Cornell Medical College , New York , NY 10065 , USA
| | - Thomas Reiner
- Department of Radiology , Memorial Sloan Kettering Cancer Center , New York , NY 10065 , USA .
- Department of Radiology , Weill Cornell Medical College , New York , NY 10065 , USA
| |
Collapse
|
27
|
Lameijer M, Binderup T, van Leent MMT, Senders ML, Fay F, Malkus J, Sanchez-Gaytan BL, Teunissen AJP, Karakatsanis N, Robson P, Zhou X, Ye Y, Wojtkiewicz G, Tang J, Seijkens TTP, Kroon J, Stroes ESG, Kjaer A, Ochando J, Reiner T, Pérez-Medina C, Calcagno C, Fisher EA, Zhang B, Temel RE, Swirski FK, Nahrendorf M, Fayad ZA, Lutgens E, Mulder WJM, Duivenvoorden R. Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates. Nat Biomed Eng 2018; 2:279-292. [PMID: 30936448 PMCID: PMC6447057 DOI: 10.1038/s41551-018-0221-2] [Citation(s) in RCA: 84] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 03/13/2018] [Indexed: 02/07/2023]
Abstract
Macrophage accumulation in atherosclerosis is directly linked to the destabilization and rupture of plaque, causing acute atherothrombotic events. Circulating monocytes enter the plaque and differentiate into macrophages, where they are activated by CD4+ T lymphocytes through CD40-CD40 ligand signalling. Here, we report the development and multiparametric evaluation of a nanoimmunotherapy that moderates CD40-CD40 ligand signalling in monocytes and macrophages by blocking the interaction between CD40 and tumour necrosis factor receptor-associated factor 6 (TRAF6). We evaluated the biodistribution characteristics of the nanoimmunotherapy in apolipoprotein E-deficient (Apoe-/-) mice and in non-human primates by in vivo positron-emission tomography imaging. In Apoe-/- mice, a 1-week nanoimmunotherapy treatment regimen achieved significant anti-inflammatory effects, which was due to the impaired migration capacity of monocytes, as established by a transcriptome analysis. The rapid reduction of plaque inflammation by the TRAF6-targeted nanoimmunotherapy and its favourable toxicity profiles in both mice and non-human primates highlights the translational potential of this strategy for the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Marnix Lameijer
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Tina Binderup
- Cluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Mandy M T van Leent
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Joost Malkus
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Brenda L Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Abraham J P Teunissen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Nicolas Karakatsanis
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Philip Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Xianxiao Zhou
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Yuxiang Ye
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Gregory Wojtkiewicz
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Tom T P Seijkens
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Jeffrey Kroon
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands
| | - Erik S G Stroes
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands
| | - Andreas Kjaer
- Cluster for Molecular Imaging and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - Jordi Ochando
- Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Edward A Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY, USA
| | - Bin Zhang
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Ryan E Temel
- Saha Cardiovascular Research Center and Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA
| | - Filip K Swirski
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Esther Lutgens
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig-Maximilians University, Munich, Germany
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands.
| | - Raphaël Duivenvoorden
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Academic Medical Center, Amsterdam, The Netherlands.
- Department of Nephrology, Academic Medical Center, Amsterdam, The Netherlands.
| |
Collapse
|
28
|
Abstract
Nature is an inspirational source for biomedical engineering developments. Particularly, numerous nanotechnological approaches have been derived from biological concepts. For example, among many different biological nanosized materials, viruses have been extensively studied and utilized, while exosome research has gained much traction in the 21st century. In our body, fat is transported by lipoproteins, intriguing supramolecular nanostructures that have important roles in cell function, lipid metabolism, and disease. Lipoproteins' main constituents are phospholipids and apolipoproteins, forming a corona that encloses a hydrophobic core of triglycerides and cholesterol esters. Within the lipoprotein family, high-density lipoprotein (HDL), primarily composed of apolipoprotein A1 (apoA-I) and phospholipids, measuring a mere 10 nm, is the smallest and densest particle. Its endogenous character makes HDL particularly suitable as a nanocarrier platform to target a range of inflammatory diseases. For a decade and a half, our laboratories have focused on HDL's exploitation, repurposing, and reengineering for diagnostic and therapeutic applications, generating versatile hybrid nanomaterials, referred to as nanobiologics, that are inherently biocompatible and biodegradable, efficiently cross different biological barriers, and intrinsically interact with immune cells. The latter is facilitated by HDL's intrinsic ability to interact with the ATP-binding cassette receptor A1 (ABCA1) and ABCG1, as well as scavenger receptor type B1 (SR-BI). In this Account, we will provide an up-to-date overview on the available methods for extraction, isolation, and purification of apoA-I from native HDL, as well as its recombinant production. ApoA-I's subsequent use for the reconstitution of HDL (rHDL) and other HDL-derived nanobiologics, including innovative microfluidic-based production methods, and their characterization will be discussed. The integration of different hydrophobic and amphiphilic imaging labels, including chelated radioisotopes and paramagnetic or fluorescent lipids, renders HDL nanobiologics suitable for diagnostic purposes. Nanoengineering also allows HDL reconstitution with core payloads, such as diagnostically active nanocrystals, as well as hydrophobic drugs or controlled release polymers for therapeutic purposes. The platform technology's specificity for inflammatory myeloid cells and methods to modulate specificity will be highlighted. This Account will build toward examples of in vivo studies in cardiovascular disease and cancer models, including diagnostic studies by magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET). A translational success story about the escalation of zirconium-89 radiolabeled HDL (89Zr-HDL) PET imaging from atherosclerotic mice to rabbits and pigs and all the way to cardiovascular disease patients is highlighted. Finally, recent advances in nanobiologic-facilitated immunotherapy of inflammation are spotlighted. Lessons, success stories, and perspectives on the use of these nature-inspired HDL mimetics are an integral part of this Account.
Collapse
Affiliation(s)
- Willem J. M. Mulder
- Translational
and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
- Department
of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Mandy M. T. van Leent
- Translational
and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
- Department
of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Marnix Lameijer
- Department
of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Edward A. Fisher
- Department
of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program
in Vascular Biology, NYU School of Medicine, New York, New York 10016, United States
| | - Zahi A. Fayad
- Translational
and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
| | - Carlos Pérez-Medina
- Translational
and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, United States
| |
Collapse
|
29
|
Senders ML, Lobatto ME, Soler R, Lairez O, Pérez-Medina C, Calcagno C, Fayad ZA, Mulder WJM, Fay F. Development and Multiparametric Evaluation of Experimental Atherosclerosis in Rabbits. Methods Mol Biol 2018; 1816:385-400. [PMID: 29987836 DOI: 10.1007/978-1-4939-8597-5_30] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Several animal models have been developed to study atherosclerosis. Here we present a rabbit atherosclerosis model generated by surgical denudation of the aortic endothelium in combination with a high-fat and cholesterol-enriched diet. This model is characterized by the formation of vascular lesions that exhibit several hallmarks of human atherosclerosis. Due to the rabbit's relative large size, as compared to rodents, this model is suited for the imaging-guided evaluation of novel therapeutic strategies using clinical scanners. In this chapter, we present an extensive outline of the procedures to induce aortic atherosclerotic lesions in rabbits as well as methods to evaluate the disease, including noninvasive in vivo multiparametric imaging and histopathology.
Collapse
Affiliation(s)
- Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Mark E Lobatto
- Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
| | - Raphael Soler
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Vascular and Endovascular Surgery, Timone Hospital, Marseille, France
| | - Olivier Lairez
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Cardiac Imaging Center, University Hospital of Toulouse, Toulouse, France
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.,Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. .,Department of Chemistry and Pharmaceutical Science, York College of the City University of New York, Jamaica, NY, USA.
| |
Collapse
|
30
|
Pérez-Medina C, Hak S, Reiner T, Fayad ZA, Nahrendorf M, Mulder WJM. Integrating nanomedicine and imaging. Philos Trans A Math Phys Eng Sci 2017; 375:rsta.2017.0110. [PMID: 29038380 PMCID: PMC5647268 DOI: 10.1098/rsta.2017.0110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 07/10/2017] [Indexed: 05/05/2023]
Abstract
Biomedical engineering and its associated disciplines play a pivotal role in improving our understanding and management of disease. Motivated by past accomplishments, such as the clinical implementation of coronary stents, pacemakers or recent developments in antibody therapies, disease management now enters a new era in which precision imaging and nanotechnology-enabled therapeutics are maturing to clinical translation. Preclinical molecular imaging increasingly focuses on specific components of the immune system that drive disease progression and complications, allowing the in vivo study of potential therapeutic targets. The first multicentre trials highlight the potential of clinical multimodality imaging for more efficient drug development. In this perspective, the role of integrating engineering, nanotechnology, molecular imaging and immunology to yield precision medicine is discussed.This article is part of the themed issue 'Challenges for chemistry in molecular imaging'.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Department of Radiology, Icahn School of Medicine at Mount Sinai, Translational and Molecular Imaging Institute, One Gustave L. Levy Place, Box 1234, New York, NY 10029, USA
| | - Sjoerd Hak
- Department of Circulation and Medical Imaging, The Norwegian University of Science and Technology, 7030 Trondheim, Norway
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
- Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Zahi A Fayad
- Department of Radiology, Icahn School of Medicine at Mount Sinai, Translational and Molecular Imaging Institute, One Gustave L. Levy Place, Box 1234, New York, NY 10029, USA
| | - Matthias Nahrendorf
- Center for Systems Biology and Department of Imaging, Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
- Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
| | - Willem J M Mulder
- Department of Radiology, Icahn School of Medicine at Mount Sinai, Translational and Molecular Imaging Institute, One Gustave L. Levy Place, Box 1234, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, The Netherlands
| |
Collapse
|
31
|
Brand C, Iacono P, Pérez-Medina C, Mulder WJM, Kircher MF, Reiner T. Specific Binding of Liposomal Nanoparticles through Inverse Electron-Demand Diels-Alder Click Chemistry. ChemistryOpen 2017; 6:615-619. [PMID: 29046855 PMCID: PMC5641912 DOI: 10.1002/open.201700105] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Indexed: 12/12/2022] Open
Abstract
Here, we report a method to specifically bind liposomal radiopharmaceuticals to a CoCrMo alloy, which can be used in arterial stents, via an irreversible inverse electron‐demand Diels–Alder reaction. Inspired by recent accomplishments in pre‐targeted imaging using tetrazine‐trans‐cyclooctene click chemistry, we synthesized 89Zr‐labeled trans‐cyclooctene‐functionalized liposomal nanoparticles, which were validated on a tetrazine‐appended polydopamine‐coated CoCrMo surface. In efforts to ultimately translate this new material to biomedical applications, we compared the ability of 89Zr‐TCO–liposomal nanoparticles (89Zr‐TCO‐LNP) to be immobilized on the tetrazine surface to the control suspensions of non‐TCO functionalized 89Zr‐liposomal nanoparticles. Ultimately, this platform technology could result in a systemic decrease of the radiotherapeutic dose deposited in non‐targeted tissues by specific removal of long‐circulating liposomal radiopharmaceuticals from the blood pool.
Collapse
Affiliation(s)
- Christian Brand
- Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA
| | - Pasquale Iacono
- Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging InstituteIcahn School of Medicine at Mount Sinai 1470 Madison Ave New York NY 10029 USA
| | - Willem J M Mulder
- Translational and Molecular Imaging InstituteIcahn School of Medicine at Mount Sinai 1470 Madison Ave New York NY 10029 USA.,Department of Medical Biochemistry Academic Medical Center Meibergdreef 91105 AZ Amsterdam The Netherlands
| | - Moritz F Kircher
- Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA.,Department of Radiology Weill Cornell Medical College 1300 York Avenue New York NY 10065 USA.,Center for Molecular Imaging & Nanotechnology (CMINT) Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA.,Molecular Pharmacology Program Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA
| | - Thomas Reiner
- Department of Radiology Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA.,Department of Radiology Weill Cornell Medical College 1300 York Avenue New York NY 10065 USA.,Center for Molecular Imaging & Nanotechnology (CMINT) Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 USA
| |
Collapse
|
32
|
Alaarg A, Senders ML, Varela-Moreira A, Pérez-Medina C, Zhao Y, Tang J, Fay F, Reiner T, Fayad ZA, Hennink WE, Metselaar JM, Mulder WJM, Storm G. A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. J Control Release 2017; 262:47-57. [PMID: 28700897 DOI: 10.1016/j.jconrel.2017.07.013] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 06/27/2017] [Accepted: 07/07/2017] [Indexed: 12/21/2022]
Abstract
Atherosclerosis is a leading cause of worldwide morbidity and mortality whose management could benefit from novel targeted therapeutics. Nanoparticles are emerging as targeted drug delivery systems in chronic inflammatory disorders. To optimally exploit nanomedicines, understanding their biological behavior is crucial for further development of clinically relevant and efficacious nanotherapeutics intended to reduce plaque inflammation. Here, three clinically relevant nanomedicines, i.e., high-density lipoprotein ([S]-HDL), polymeric micelles ([S]-PM), and liposomes ([S]-LIP), that are loaded with the HMG-CoA reductase inhibitor simvastatin [S], were evaluated in the apolipoprotein E-deficient (Apoe-/-) mouse model of atherosclerosis. We systematically employed quantitative techniques, including in vivo positron emission tomography imaging, gamma counting, and flow cytometry to evaluate the biodistribution, nanomedicines' uptake by plaque-associated macrophages/monocytes, and their efficacy to reduce macrophage burden in atherosclerotic plaques. The three formulations demonstrated distinct biological behavior in Apoe-/- mice. While [S]-PM and [S]-LIP possessed longer circulation half-lives, the three platforms accumulated to similar levels in atherosclerotic plaques. Moreover, [S]-HDL and [S]-PM showed higher uptake by plaque macrophages in comparison to [S]-LIP, while [S]-PM demonstrated the highest uptake by Ly6Chigh monocytes. Among the three formulations, [S]-PM displayed the highest efficacy in reducing macrophage burden in advanced atherosclerotic plaques. In conclusion, our data demonstrate that [S]-PM is a promising targeted drug delivery system, which can be advanced for the treatment of atherosclerosis and other inflammatory disorders in the clinical settings. Our results also emphasize the importance of a thorough understanding of nanomedicines' biological performance, ranging from the whole body to the target cells, as well drug retention in the nanoparticles. Such systematic investigations would allow rational applications of nanomaterials', beyond cancer, facilitating the expansion of the nanomedicine horizon.
Collapse
Affiliation(s)
- Amr Alaarg
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands
| | - Max L Senders
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Aida Varela-Moreira
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands; Department of Clinical Chemistry and Haematology, University Medical Centre Utrecht, Utrecht 3584 CX, The Netherlands
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Chemistry, York College of The City University of New York, New York, NY 11451, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Wim E Hennink
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands
| | - Josbert M Metselaar
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Department of Experimental Molecular Imaging, University Clinic and Helmholtz Institute for Biomedical Engineering, RWTH Aachen University, Aachen 52074, Germany
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands.
| | - Gert Storm
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede 7500 AE, The Netherlands; Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands; Imaging Division, University Medical Centre Utrecht, Utrecht 3584 CX, The Netherlands.
| |
Collapse
|
33
|
Beldman TJ, Senders ML, Alaarg A, Pérez-Medina C, Tang J, Zhao Y, Fay F, Deichmöller J, Born B, Desclos E, van der Wel NN, Hoebe RA, Kohen F, Kartvelishvily E, Neeman M, Reiner T, Calcagno C, Fayad ZA, de Winther MPJ, Lutgens E, Mulder WJM, Kluza E. Hyaluronan Nanoparticles Selectively Target Plaque-Associated Macrophages and Improve Plaque Stability in Atherosclerosis. ACS Nano 2017; 11:5785-5799. [PMID: 28463501 PMCID: PMC5492212 DOI: 10.1021/acsnano.7b01385] [Citation(s) in RCA: 113] [Impact Index Per Article: 16.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 05/02/2017] [Indexed: 05/18/2023]
Abstract
Hyaluronan is a biologically active polymer, which can be formulated into nanoparticles. In our study, we aimed to probe atherosclerosis-associated inflammation by using hyaluronan nanoparticles and to determine whether they can ameliorate atherosclerosis. Hyaluronan nanoparticles (HA-NPs) were prepared by reacting amine-functionalized oligomeric hyaluronan (HA) with cholanic ester and labeled with a fluorescent or radioactive label. HA-NPs were characterized in vitro by several advanced microscopy methods. The targeting properties and biodistribution of HA-NPs were studied in apoe-/- mice, which received either fluorescent or radiolabeled HA-NPs and were examined ex vivo by flow cytometry or nuclear techniques. Furthermore, three atherosclerotic rabbits received 89Zr-HA-NPs and were imaged by PET/MRI. The therapeutic effects of HA-NPs were studied in apoe-/- mice, which received weekly doses of 50 mg/kg HA-NPs during a 12-week high-fat diet feeding period. Hydrated HA-NPs were ca. 90 nm in diameter and displayed very stable morphology under hydrolysis conditions. Flow cytometry revealed a 6- to 40-fold higher uptake of Cy7-HA-NPs by aortic macrophages compared to normal tissue macrophages. Interestingly, both local and systemic HA-NP-immune cell interactions significantly decreased over the disease progression. 89Zr-HA-NPs-induced radioactivity in atherosclerotic aortas was 30% higher than in wild-type controls. PET imaging of rabbits revealed 6-fold higher standardized uptake values compared to the muscle. The plaques of HA-NP-treated mice contained 30% fewer macrophages compared to control and free HA-treated group. In conclusion, we show favorable targeting properties of HA-NPs, which can be exploited for PET imaging of atherosclerosis-associated inflammation. Furthermore, we demonstrate the anti-inflammatory effects of HA-NPs in atherosclerosis.
Collapse
Affiliation(s)
- Thijs J. Beldman
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | - Max L. Senders
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | - Amr Alaarg
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
- Department
of Biomaterials Science and Technology, MIRA Institute for Biomedical
Technology and Technical Medicine, University
of Twente, Enschede 7522 NB, The Netherlands
| | - Carlos Pérez-Medina
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Jun Tang
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
- Department of Radiology, Memorial Sloan
Kettering Cancer Center, New York, New York 10065, United States
| | - Yiming Zhao
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Francois Fay
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Jacqueline Deichmöller
- Department of Biological Regulation and Department of Chemical Research
Support, Weizmann Institute of Science, Rehovot 7610001, Israel
- Physical Chemistry II, Ruhr-Universität Bochum, Bochum 44801, Germany
| | - Benjamin Born
- Department of Biological Regulation and Department of Chemical Research
Support, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Emilie Desclos
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | - Nicole N. van der Wel
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | - Ron A. Hoebe
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
| | - Fortune Kohen
- Department of Biological Regulation and Department of Chemical Research
Support, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Elena Kartvelishvily
- Department of Biological Regulation and Department of Chemical Research
Support, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Michal Neeman
- Department of Biological Regulation and Department of Chemical Research
Support, Weizmann Institute of Science, Rehovot 7610001, Israel
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan
Kettering Cancer Center, New York, New York 10065, United States
- Department of Radiology, Weill Cornell Medical College, New York, New York 10065, United States
| | - Claudia Calcagno
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Zahi A. Fayad
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Menno P. J. de Winther
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, Munich 80336, Germany
| | - Esther Lutgens
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
- Institute for Cardiovascular Prevention, Ludwig Maximilians University, Munich 80336, Germany
| | - Willem J. M. Mulder
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
- Department of Radiology, Mount Sinai School of Medicine, New York, New York 10029, United States
| | - Ewelina Kluza
- Experimental
Vascular Biology, Department of Medical Biochemistry,
and Cellular Imaging, AMC
Core Facility, Academic Medical Center, Amsterdam 1105 AZ, The Netherlands
- E-mail: . Tel: +31(0)205665296
| |
Collapse
|
34
|
Fay F, Hansen L, Hectors SJCG, Sanchez-Gaytan BL, Zhao Y, Tang J, Munitz J, Alaarg A, Braza MS, Gianella A, Aaronson SA, Reiner T, Kjems J, Langer R, Hoeben FJM, Janssen HM, Calcagno C, Strijkers GJ, Fayad ZA, Pérez-Medina C, Mulder WJM. Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging. Bioconjug Chem 2017; 28:1413-1421. [PMID: 28316241 DOI: 10.1021/acs.bioconjchem.7b00086] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Active targeting of nanoparticles through surface functionalization is a common strategy to enhance tumor delivery specificity. However, active targeting strategies tend to work against long polyethylene glycol's shielding effectiveness and associated favorable pharmacokinetics. To overcome these limitations, we developed a matrix metalloproteinase-2 sensitive surface-converting polyethylene glycol coating. This coating prevents nanoparticle-cell interaction in the bloodstream, but, once exposed to matrix metalloproteinase-2, i.e., when the nanoparticles accumulate within the tumor interstitium, the converting polyethylene glycol coating is cleaved, and targeting ligands become available for binding to tumor cells. In this study, we applied a comprehensive multimodal imaging strategy involving optical, nuclear, and magnetic resonance imaging methods to evaluate this coating approach in a breast tumor mouse model. The data obtained revealed that this surface-converting coating enhances the nanoparticle's blood half-life and tumor accumulation and ultimately results in improved tumor-cell targeting. Our results show that this enzyme-specific surface-converting coating ensures a high cell-targeting specificity without compromising favorable nanoparticle pharmacokinetics.
Collapse
Affiliation(s)
| | - Line Hansen
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University , Aarhus DK-8000, Denmark
| | | | | | | | - Jun Tang
- Department of Radiology, Memorial Sloan-Kettering Cancer Center , New York City, New York 10065, United States
| | | | - Amr Alaarg
- Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente , Enschede 7522 NB, The Netherlands
| | | | | | | | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center , New York City, New York 10065, United States
| | - Jørgen Kjems
- Interdisciplinary Nanoscience Center (iNANO), Aarhus University , Aarhus DK-8000, Denmark
| | - Robert Langer
- Department of Chemical Engineering, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Sanchez-Gaytan BL, Fay F, Hak S, Alaarg A, Fayad ZA, Pérez-Medina C, Mulder WJM, Zhao Y. Real-Time Monitoring of Nanoparticle Formation by FRET Imaging. Angew Chem Int Ed Engl 2017; 56:2923-2926. [PMID: 28112478 PMCID: PMC5589959 DOI: 10.1002/anie.201611288] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2016] [Revised: 12/15/2016] [Indexed: 12/25/2022]
Abstract
Understanding the formation process of nanoparticles is of the utmost importance to improve their design and production. This especially holds true for self-assembled nanoparticles whose formation processes have been largely overlooked. Herein, we present a new technology that integrates a microfluidic-based nanoparticle synthesis method and Förster resonance energy transfer (FRET) microscopy imaging to visualize nanoparticle self-assembly in real time. Applied to different nanoparticle systems, for example, nanoemulsions, drug-loaded block-copolymer micelles, and nanocrystal-core reconstituted high-density lipoproteins, we have shown the approach's unique ability to investigate key parameters affecting nanoparticle formation.
Collapse
Affiliation(s)
- Brenda L. Sanchez-Gaytan
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
| | - François Fay
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
| | - Sjoerd Hak
- Department of Circulation and Medical Imaging, The Norwegian University of Science and Technology, 7030 Trondheim, Norway
| | - Amr Alaarg
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute, University of Twente, Ensche-de, 7500 AE, The Netherlands
| | - Zahi A. Fayad
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
| | - Willem J. M. Mulder
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
- Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Yiming Zhao
- Translational and Molecular Imaging Institute Icahn School of Medicine at Mount Sinai New York, New York. 10029, USA
| |
Collapse
|
36
|
Tang J, Pérez-Medina C, Zhao Y, Sadique A, Mulder WJM, Reiner T. A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines. J Vis Exp 2017. [PMID: 28287606 DOI: 10.3791/55271] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Inspired by the success of previous cancer nanomedicines in the clinic, researchers have generated a large number of novel formulations in the past decade. However, only a small number of nanomedicines have been approved for clinical use, whereas the majority of nanomedicines under clinical development have produced disappointing results. One major obstacle to the successful clinical translation of new cancer nanomedicines is the lack of an accurate understanding of their in vivo performance. This article features a rigorous procedure to characterize the in vivo behavior of nanomedicines in tumor-bearing mice at systemic, tissue, single-cell, and subcellular levels via the integration of positron emission tomography-computed tomography (PET-CT), radioactivity quantification methods, flow cytometry, and fluorescence microscopy. Using this approach, researchers can accurately evaluate novel nanoscale formulations in relevant mouse models of cancer. These protocols may have the ability to identify the most promising cancer nanomedicines with high translational potential or to aid in the optimization of cancer nanomedicines for future translation.
Collapse
Affiliation(s)
- Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center;
| | - Carlos Pérez-Medina
- Department of Radiology, Memorial Sloan Kettering Cancer Center; Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai
| | - Ahmad Sadique
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center
| |
Collapse
|
37
|
Sanchez-Gaytan BL, Fay F, Hak S, Alaarg A, Fayad ZA, Pérez-Medina C, Mulder WJM, Zhao Y. Real-Time Monitoring of Nanoparticle Formation by FRET Imaging. Angew Chem Int Ed Engl 2017. [DOI: 10.1002/ange.201611288] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Brenda L. Sanchez-Gaytan
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
| | - François Fay
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
| | - Sjoerd Hak
- Department of Circulation and Medical Imaging; The Norwegian University of Science and Technology; 7030 Trondheim Norway
| | - Amr Alaarg
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
- Department of Biomaterials Science and Technology, Targeted Therapeutics section, MIRA Institute; University of Twente; Enschede 7500 AE The Netherlands
| | - Zahi A. Fayad
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
| | - Willem J. M. Mulder
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
- Department of Medical Biochemistry; Academic Medical Center; 1105 AZ Amsterdam The Netherlands
| | - Yiming Zhao
- Translational and Molecular Imaging Institute; Icahn School of Medicine at Mount Sinai; New York NY 10029 USA
| |
Collapse
|
38
|
Zhao Y, Shaffer TM, Das S, Pérez-Medina C, Mulder WJM, Grimm J. Near-Infrared Quantum Dot and 89Zr Dual-Labeled Nanoparticles for in Vivo Cerenkov Imaging. Bioconjug Chem 2017; 28:600-608. [PMID: 28026929 DOI: 10.1021/acs.bioconjchem.6b00687] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Cerenkov luminescence (CL) is an emerging imaging modality that utilizes the light generated during the radioactive decay of many clinical used isotopes. Although it is increasingly used for background-free imaging and deep tissue photodynamic therapy, in vivo applications of CL suffer from limited tissue penetration. Here, we propose to use quantum dots (QDs) as spectral converters that can transfer the CL UV-blue emissions to near-infrared light that is less scattered or absorbed in vivo. Experiments on tissue phantoms showed enhanced penetration depth and increased transmitted intensity for CL in the presence of near-infrared (NIR) QDs. To realize this concept for in vivo imaging applications, we developed three types of NIR QDs and 89Zr dual-labeled nanoparticles based on lipid micelles, nanoemulsions, and polymeric nanoplatforms, which enable codelivery of the radionuclide and the QDs for maximized spectral conversion efficiency. We finally demonstrated the application of these self-illuminating nanoparticles for imaging of lymph nodes and tumors in a prostate cancer mouse model.
Collapse
Affiliation(s)
- Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States
| | - Travis M Shaffer
- Department of Chemistry, Hunter College and the Graduate Center of the City University of New York , New York, New York 10065, United States
| | | | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.,Department of Medical Biochemistry, Academic Medical Center , Amsterdam, 1105 AZ, The Netherlands
| | - Jan Grimm
- Pharmacology Program & Department of Radiology, Weill Cornell Medical College, Cornell University , New York, New York 10065, United States
| |
Collapse
|
39
|
Affiliation(s)
- Max L Senders
- Translational & Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Zahi A Fayad
- Translational & Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.,Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA
| | - Willem Jm Mulder
- Translational & Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.,Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Carlos Pérez-Medina
- Translational & Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| |
Collapse
|
40
|
Pérez-Medina C, Abdel-Atti D, Tang J, Zhao Y, Fayad ZA, Lewis JS, Mulder WJM, Reiner T. Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. Nat Commun 2016; 7:11838. [PMID: 27319780 PMCID: PMC4915130 DOI: 10.1038/ncomms11838] [Citation(s) in RCA: 81] [Impact Index Per Article: 10.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 05/05/2016] [Indexed: 02/07/2023] Open
Abstract
The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (89Zr-NRep) allows precise doxorubicin (DOX) quantification. Importantly, 89Zr-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. 89Zr-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with >25 mg kg−1 DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy. Nanoparticle drug formulations are currently used as cancer treatment but the response in patients is highly variable. Here, the authors developed a Zirconium-89 nanoreporter able to predict using PET, therapeutic accumulation and efficacy of anti-cancer nanoparticle drug formulations when co-injected in a murine breast cancer model.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.,Centro de Investigación en Red de Enfermedades Respiratorias, 28029 Madrid, Spain.,Advanced Imaging Unit, Centro Nacional de Investigaciones Cardiovasculares, CNIC, 28029 Madrid, Spain
| | - Dalya Abdel-Atti
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New York 10065, USA
| | - Jun Tang
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New York 10065, USA
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA
| | - Jason S Lewis
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New York 10065, USA.,Department of Radiology, Weill Cornell Medical College, New York, New York 10065, USA.,Molecular Pharmacology &Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.,Department of Medical Biochemistry, Academic Medical Center, 1105 AZ Amsterdam, The Netherlands
| | - Thomas Reiner
- Memorial Sloan Kettering Cancer Center, Department of Radiology, New York, New York 10065, USA.,Department of Radiology, Weill Cornell Medical College, New York, New York 10065, USA
| |
Collapse
|
41
|
Pérez-Medina C, Binderup T, Lobatto ME, Tang J, Calcagno C, Giesen L, Wessel CH, Witjes J, Ishino S, Baxter S, Zhao Y, Ramachandran S, Eldib M, Sánchez-Gaytán BL, Robson PM, Bini J, Granada JF, Fish KM, Stroes ESG, Duivenvoorden R, Tsimikas S, Lewis JS, Reiner T, Fuster V, Kjær A, Fisher EA, Fayad ZA, Mulder WJM. In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. JACC Cardiovasc Imaging 2016; 9:950-61. [PMID: 27236528 DOI: 10.1016/j.jcmg.2016.01.020] [Citation(s) in RCA: 67] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2015] [Revised: 01/13/2016] [Accepted: 01/13/2016] [Indexed: 01/08/2023]
Abstract
OBJECTIVES The goal of this study was to develop and validate a noninvasive imaging tool to visualize the in vivo behavior of high-density lipoprotein (HDL) by using positron emission tomography (PET), with an emphasis on its plaque-targeting abilities. BACKGROUND HDL is a natural nanoparticle that interacts with atherosclerotic plaque macrophages to facilitate reverse cholesterol transport. HDL-cholesterol concentration in blood is inversely associated with risk of coronary heart disease and remains one of the strongest independent predictors of incident cardiovascular events. METHODS Discoidal HDL nanoparticles were prepared by reconstitution of its components apolipoprotein A-I (apo A-I) and the phospholipid 1,2-dimyristoyl-sn-glycero-3-phosphocholine. For radiolabeling with zirconium-89 ((89)Zr), the chelator deferoxamine B was introduced by conjugation to apo A-I or as a phospholipid-chelator (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-deferoxamine B). Biodistribution and plaque targeting of radiolabeled HDL were studied in established murine, rabbit, and porcine atherosclerosis models by using PET combined with computed tomography (PET/CT) imaging or PET combined with magnetic resonance imaging. Ex vivo validation was conducted by radioactivity counting, autoradiography, and near-infrared fluorescence imaging. Flow cytometric assessment of cellular specificity in different tissues was performed in the murine model. RESULTS We observed distinct pharmacokinetic profiles for the two (89)Zr-HDL nanoparticles. Both apo A-I- and phospholipid-labeled HDL mainly accumulated in the kidneys, liver, and spleen, with some marked quantitative differences in radioactivity uptake values. Radioactivity concentrations in rabbit atherosclerotic aortas were 3- to 4-fold higher than in control animals at 5 days' post-injection for both (89)Zr-HDL nanoparticles. In the porcine model, increased accumulation of radioactivity was observed in lesions by using in vivo PET imaging. Irrespective of the radiolabel's location, HDL nanoparticles were able to preferentially target plaque macrophages and monocytes. CONCLUSIONS (89)Zr labeling of HDL allows study of its in vivo behavior by using noninvasive PET imaging, including visualization of its accumulation in advanced atherosclerotic lesions. The different labeling strategies provide insight on the pharmacokinetics and biodistribution of HDL's main components (i.e., phospholipids, apo A-I).
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Tina Binderup
- Clinical Physiology, Nuclear Medicine, PET and Cluster for Molecular Imaging, University of Copenhagen, Copenhagen, Denmark
| | - Mark E Lobatto
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
| | - Jun Tang
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Luuk Giesen
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Chang Ho Wessel
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Julia Witjes
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Seigo Ishino
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Samantha Baxter
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Yiming Zhao
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Mootaz Eldib
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Brenda L Sánchez-Gaytán
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Philip M Robson
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Jason Bini
- School of Engineering & Applied Science, Yale University, New Haven, Connecticut
| | - Juan F Granada
- CRF Skirball Center for Innovation, The Cardiovascular Research Foundation, Orangeburg, New York
| | - Kenneth M Fish
- Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Erik S G Stroes
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
| | - Raphaël Duivenvoorden
- Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
| | - Sotirios Tsimikas
- Division of Cardiovascular Diseases, Department of Medicine, University of California San Diego, La Jolla, California
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Valentín Fuster
- Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Andreas Kjær
- Clinical Physiology, Nuclear Medicine and PET, University of Copenhagen, Copenhagen, Denmark
| | - Edward A Fisher
- Leon H. Charney Division of Cardiology and Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, the Netherlands.
| |
Collapse
|
42
|
Ye YX, Calcagno C, Binderup T, Courties G, Keliher EJ, Wojtkiewicz GR, Iwamoto Y, Tang J, Pérez-Medina C, Mani V, Ishino S, Johnbeck CB, Knigge U, Fayad ZA, Libby P, Weissleder R, Tawakol A, Dubey S, Belanger AP, Di Carli MF, Swirski FK, Kjaer A, Mulder WJM, Nahrendorf M. Imaging Macrophage and Hematopoietic Progenitor Proliferation in Atherosclerosis. Circ Res 2015; 117:835-45. [PMID: 26394773 DOI: 10.1161/circresaha.115.307024] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Accepted: 09/22/2015] [Indexed: 12/31/2022]
Abstract
RATIONALE Local plaque macrophage proliferation and monocyte production in hematopoietic organs promote progression of atherosclerosis. Therefore, noninvasive imaging of proliferation could serve as a biomarker and monitor therapeutic intervention. OBJECTIVE To explore (18)F-FLT positron emission tomography-computed tomography imaging of cell proliferation in atherosclerosis. METHODS AND RESULTS (18)F-FLT positron emission tomography-computed tomography was performed in mice, rabbits, and humans with atherosclerosis. In apolipoprotein E knock out mice, increased (18)F-FLT signal was observed in atherosclerotic lesions, spleen, and bone marrow (standardized uptake values wild-type versus apolipoprotein E knock out mice, 0.05 ± 0.01 versus 0.17 ± 0.01, P<0.05 in aorta; 0.13 ± 0.01 versus 0.28 ± 0.02, P<0.05 in bone marrow; 0.06 ± 0.01 versus 0.22 ± 0.01, P<0.05 in spleen), corroborated by ex vivo scintillation counting and autoradiography. Flow cytometry confirmed significantly higher proliferation of macrophages in aortic lesions and hematopoietic stem and progenitor cells in the spleen and bone marrow in these mice. In addition, (18)F-FLT plaque signal correlated with the duration of high cholesterol diet (r(2)=0.33, P<0.05). Aortic (18)F-FLT uptake was reduced when cell proliferation was suppressed with fluorouracil in apolipoprotein E knock out mice (P<0.05). In rabbits, inflamed atherosclerotic vasculature with the highest (18)F-fluorodeoxyglucose uptake enriched (18)F-FLT. In patients with atherosclerosis, (18)F-FLT signal significantly increased in the inflamed carotid artery and in the aorta. CONCLUSIONS (18)F-FLT positron emission tomography imaging may serve as an imaging biomarker for cell proliferation in plaque and hematopoietic activity in individuals with atherosclerosis.
Collapse
Affiliation(s)
- Yu-Xiang Ye
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Claudia Calcagno
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Tina Binderup
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Gabriel Courties
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Edmund J Keliher
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Gregory R Wojtkiewicz
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Yoshiko Iwamoto
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Jun Tang
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Carlos Pérez-Medina
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Venkatesh Mani
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Seigo Ishino
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Camilla Bardram Johnbeck
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Ulrich Knigge
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Zahi A Fayad
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Peter Libby
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Ralph Weissleder
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Ahmed Tawakol
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Shipra Dubey
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Anthony P Belanger
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Marcelo F Di Carli
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Filip K Swirski
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Andreas Kjaer
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Willem J M Mulder
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.)
| | - Matthias Nahrendorf
- From the Center for Systems Biology, Department of Radiology (Y.-X.Y., G.C., E.J.K., G.R.W., Y.I., R.W., F.K.S., M.N.) and Division of Cardiology (A.T.), Massachusetts General Hospital and Harvard Medical School, Boston; Translational and Molecular Imaging Institute, Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY (C.C., J.T., C.P.-M., V.M., S.I., Z.A.F., W.J.M.M.); Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging (T.B., C.B.J., A.K.) and Departments of Clinical Endocrinology PE and Surgery C (U.K.), Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (P.L., M.F.D.C.); Department of Systems Biology, Harvard Medical School, Boston, MA (R.W.); Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (S.D., A.P.B., M.F.D.C.); and Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands (W.J.M.M.).
| |
Collapse
|
43
|
Pérez-Medina C, Tang J, Abdel-Atti D, Hogstad B, Merad M, Fisher EA, Fayad ZA, Lewis JS, Mulder WJM, Reiner T. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. J Nucl Med 2015; 56:1272-7. [PMID: 26112022 DOI: 10.2967/jnumed.115.158956] [Citation(s) in RCA: 127] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2015] [Accepted: 06/04/2015] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED Tumor-associated macrophages (TAMs) are increasingly investigated in cancer immunology and are considered a promising target for better and tailored treatment of malignant growth. Although TAMs also have high diagnostic and prognostic value, TAM imaging still remains largely unexplored. Here, we describe the development of reconstituted high-density lipoprotein (rHDL)-facilitated TAM PET imaging in a breast cancer model. METHODS Radiolabeled rHDL nanoparticles incorporating the long-lived positron-emitting nuclide (89)Zr were developed using 2 different approaches. The nanoparticles were composed of phospholipids and apolipoprotein A-I (apoA-I) in a 2.5:1 weight ratio. (89)Zr was complexed with deferoxamine (also known as desferrioxamine B, desferoxamine B), conjugated either to a phospholipid or to apoA-I to generate (89)Zr-PL-HDL and (89)Zr-AI-HDL, respectively. In vivo evaluation was performed in an orthotopic mouse model of breast cancer and included pharmacokinetic analysis, biodistribution studies, and PET imaging. Ex vivo histologic analysis of tumor tissues to assess regional distribution of (89)Zr radioactivity was also performed. Fluorescent analogs of the radiolabeled agents were used to determine cell-targeting specificity using flow cytometry. RESULTS The phospholipid- and apoA-I-labeled rHDL were produced at 79% ± 13% (n = 6) and 94% ± 6% (n = 6) radiochemical yield, respectively, with excellent radiochemical purity (>99%). Intravenous administration of both probes resulted in high tumor radioactivity accumulation (16.5 ± 2.8 and 8.6 ± 1.3 percentage injected dose per gram for apoA-I- and phospholipid-labeled rHDL, respectively) at 24 h after injection. Histologic analysis showed good colocalization of radioactivity with TAM-rich areas in tumor sections. Flow cytometry revealed high specificity of rHDL for TAMs, which had the highest uptake per cell (6.8-fold higher than tumor cells for both DiO@Zr-PL-HDL and DiO@Zr-AI-HDL) and accounted for 40.7% and 39.5% of the total cellular DiO@Zr-PL-HDL and DiO@Zr-AI-HDL in tumors, respectively. CONCLUSION We have developed (89)Zr-labeled TAM imaging agents based on the natural nanoparticle rHDL. In an orthotopic mouse model of breast cancer, we have demonstrated their specificity for macrophages, a result that was corroborated by flow cytometry. Quantitative macrophage PET imaging with our (89)Zr-rHDL imaging agents could be valuable for noninvasive monitoring of TAM immunology and targeted treatment.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Centro de Investigación en Red de Enfermedades Respiratorias, CIBERES, Madrid, Spain Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Jun Tang
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Dalya Abdel-Atti
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Brandon Hogstad
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Miriam Merad
- Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Edward A Fisher
- Leon H. Charney Division of Cardiology and Marc and Ruti Bell Program in Vascular Biology, New York University School of Medicine, New York, New York
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Jason S Lewis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York; and
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York Department of Vascular Medicine, Academic Medical Center of the University of Amsterdam, Amsterdam, The Netherlands
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York; and
| |
Collapse
|
44
|
Tang J, Lobatto ME, Hassing L, van der Staay S, van Rijs SM, Calcagno C, Braza MS, Baxter S, Fay F, Sanchez-Gaytan BL, Duivenvoorden R, Sager HB, Astudillo YM, Leong W, Ramachandran S, Storm G, Pérez-Medina C, Reiner T, Cormode DP, Strijkers GJ, Stroes ESG, Swirski FK, Nahrendorf M, Fisher EA, Fayad ZA, Mulder WJM. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci Adv 2015; 1:e1400223. [PMID: 26295063 PMCID: PMC4539616 DOI: 10.1126/sciadv.1400223] [Citation(s) in RCA: 147] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2014] [Accepted: 03/05/2015] [Indexed: 05/29/2023]
Abstract
Inflammation drives atherosclerotic plaque progression and rupture, and is a compelling therapeutic target. Consequently, attenuating inflammation by reducing local macrophage accumulation is an appealing approach. This can potentially be accomplished by either blocking blood monocyte recruitment to the plaque or increasing macrophage apoptosis and emigration. Because macrophage proliferation was recently shown to dominate macrophage accumulation in advanced plaques, locally inhibiting macrophage proliferation may reduce plaque inflammation and produce long-term therapeutic benefits. To test this hypothesis, we used nanoparticle-based delivery of simvastatin to inhibit plaque macrophage proliferation in apolipoprotein E deficient mice (Apoe-/- ) with advanced atherosclerotic plaques. This resulted in rapid reduction of plaque inflammation and favorable phenotype remodeling. We then combined this short-term nanoparticle intervention with an eight-week oral statin treatment, and this regimen rapidly reduced and continuously suppressed plaque inflammation. Our results demonstrate that pharmacologically inhibiting local macrophage proliferation can effectively treat inflammation in atherosclerosis.
Collapse
Affiliation(s)
- Jun Tang
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mark E. Lobatto
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Laurien Hassing
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Susanne van der Staay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Sarian M. van Rijs
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Claudia Calcagno
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Mounia S. Braza
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Samantha Baxter
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Francois Fay
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Brenda L. Sanchez-Gaytan
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Raphaël Duivenvoorden
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Hendrik B. Sager
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Yaritzy M. Astudillo
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY 10016, USA
| | - Wei Leong
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Sarayu Ramachandran
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, Netherlands
- Department of Controlled Drug Delivery, MIRA Institute for Biomedical Engineering and Technical Medicine, University of Twente, 7500 AE Enschede, Netherlands
| | - Carlos Pérez-Medina
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Thomas Reiner
- Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - David P. Cormode
- Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Gustav J. Strijkers
- Department of Biomedical Engineering and Physics, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Erik S. G. Stroes
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| | - Filip K. Swirski
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Matthias Nahrendorf
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
| | - Edward A. Fisher
- Department of Medicine (Cardiology) and Cell Biology, Marc and Ruti Bell Program in Vascular Biology, NYU School of Medicine, New York, NY 10016, USA
| | - Zahi A. Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Willem J. M. Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
- Department of Vascular Medicine, Academic Medical Center, 1105 AZ Amsterdam, Netherlands
| |
Collapse
|
45
|
Pérez-Medina C, Abdel-Atti D, Zhang Y, Longo VA, Irwin CP, Binderup T, Ruiz-Cabello J, Fayad ZA, Lewis JS, Mulder WJM, Reiner T. A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. J Nucl Med 2014; 55:1706-11. [PMID: 25060196 DOI: 10.2967/jnumed.114.141861] [Citation(s) in RCA: 75] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
UNLABELLED Advances in preclinical molecular imaging have generated new opportunities to noninvasively visualize the biodistribution and tumor targeting of nanoparticle therapeutics. Capitalizing on recent achievements in this area, we sought to develop an (89)Zr-based labeling strategy for liposomal nanoparticles that accumulate in tumors via passive targeting mechanisms. METHODS (89)Zr-labeled liposomes were prepared using 2 different approaches: click labeling and surface chelation. Pharmacokinetic and biodistribution studies, as well as PET/CT imaging of the radiolabeled nanoparticles, were performed on a mouse model of breast cancer. In addition, a dual PET/optical probe was prepared by incorporation of a near-infrared fluorophore and tested in vivo by PET and near-infrared fluorescence imaging. RESULTS The surface chelation approach proved to be superior in terms of radiochemical yield and stability, as well as in vivo performance. Accumulation of these liposomes in tumor peaked at 24 h after injection and was measured to be 13.7 ± 1.8 percentage injected dose per gram. The in vivo performance of this probe was not essentially perturbed by the incorporation of a near-infrared fluorophore. CONCLUSION We have developed a highly modular and efficient strategy for the labeling of liposomal nanoparticles with (89)Zr. In xenograft and orthotopic mouse models of breast cancer, we demonstrated that the biodistribution of these nanoparticles can be visualized by PET imaging. In combination with a near-infrared dye, these liposomal nanoparticles can serve as bimodal PET/optical imaging agents. The liposomes target malignant growth, and their bimodal features may be useful for simultaneous PET and intraoperative imaging.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Centro de Investigación en Red de Enfermedades Respiratorias, Madrid, Spain Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Dalya Abdel-Atti
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Yachao Zhang
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Valerie A Longo
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Chrisopher P Irwin
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Tina Binderup
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York Cluster for Molecular Imaging, Faculty of Health Sciences and Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen, Denmark
| | - Jesús Ruiz-Cabello
- Centro de Investigación en Red de Enfermedades Respiratorias, Madrid, Spain Centro Nacional de Investigaciones Cardiovasculares, CNIC, Madrid, Spain
| | - Zahi A Fayad
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Jason S Lewis
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and Center for Molecular Imaging and Nanotechnology, Memorial Sloan-Kettering Cancer Center, New York, New York
| | - Willem J M Mulder
- Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Thomas Reiner
- Radiochemistry and Imaging Sciences Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York Center for Molecular Imaging and Nanotechnology, Memorial Sloan-Kettering Cancer Center, New York, New York
| |
Collapse
|
46
|
Pérez-Medina C, Patel N, Robson M, Lythgoe MF, Årstad E. Synthesis and evaluation of a 125I-labeled iminodihydroquinoline-derived tracer for imaging of voltage-gated sodium channels. Bioorg Med Chem Lett 2013; 23:5170-3. [PMID: 23910595 PMCID: PMC3764405 DOI: 10.1016/j.bmcl.2013.07.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Revised: 07/10/2013] [Accepted: 07/11/2013] [Indexed: 12/04/2022]
Abstract
In vivo imaging of voltage-gated sodium channels (VGSCs) can potentially provide insights into the activation of neuronal pathways and aid the diagnosis of a number of neurological diseases. The iminodihydroquinoline WIN17317-3 is one of the most potent sodium channel blockers reported to date and binds with high affinity to VGSCs throughout the rat brain. We have synthesized a 125I-labeled analogue of WIN17317-3 and evaluated the potential of the tracer for imaging of VGSCs with SPECT. Automated patch clamp studies with CHO cells expressing the Nav1.2 isoform and displacement studies with [3H]BTX yielded comparable results for the non-radioactive iodinated iminodihydroquinoline and WIN17317-3. However, the 125I-labeled tracer was rapidly metabolized in vivo, and suffered from low brain uptake and high accumulation of radioactivity in the intestines. The results suggest that iminodihydroquinolines are poorly suited for tracer development.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Department of Chemistry and Institute of Nuclear Medicine, UCL, 235 Euston Road (T-5), London NW1 2BU, United Kingdom
| | - Niral Patel
- Department of Chemistry and Institute of Nuclear Medicine, UCL, 235 Euston Road (T-5), London NW1 2BU, United Kingdom
- Centre for Advanced Biomedical Imaging, UCL, 72 Huntley Street, London WC1E 6BT, United Kingdom
| | - Mathew Robson
- UCL Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, United Kingdom
| | - Mark F. Lythgoe
- Centre for Advanced Biomedical Imaging, UCL, 72 Huntley Street, London WC1E 6BT, United Kingdom
| | - Erik Årstad
- Department of Chemistry and Institute of Nuclear Medicine, UCL, 235 Euston Road (T-5), London NW1 2BU, United Kingdom
- Corresponding author. Tel./fax: +44 (0)02076792344.
| |
Collapse
|
47
|
Pérez-Medina C, Patel N, Robson M, Badar A, Lythgoe MF, Årstad E. Evaluation of a 125I-labelled benzazepinone derived voltage-gated sodium channel blocker for imaging with SPECT. Org Biomol Chem 2012; 10:9474-80. [PMID: 23117159 DOI: 10.1039/c2ob26695d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Voltage-gated sodium channels (VGSCs) are a family of transmembrane proteins that mediate fast neurotransmission, and are integral to sustain physiological conditions and higher cognitive functions. Imaging of VGSCs in vivo holds promise as a tool to elucidate operational functions in the brain and to aid the treatment of a wide range of neurological diseases. To assess the suitability of 1-benzazepin-2-one derived VGSC blockers for imaging, we have prepared a (125)I-labelled analogue of BNZA and evaluated the tracer in vivo. In an automated patch-clamp assay, a diastereomeric mixture of the non-radioactive compound blocked the Na(v)1.2 and Na(v)1.7 VGSC isoforms with IC(50) values of 4.1 ± 1.5 μM and 0.25 ± 0.07 μM, respectively. [(3)H]BTX displacement studies revealed a three-fold difference in affinity between the two diastereomers. Iodo-destannylation of a tin precursor with iodine-125 afforded the two diastereomerically pure tracers, which were used to assess binding to VGSCs in vivo by comparing their tissue distributions in mice. Whilst the results point to a lack of VGSC binding in vivo, SPECT imaging revealed highly localized uptake in the interscapular region, an area typically associated with brown adipose tissue, which in addition to high metabolic stability of the iodinated tracer, demonstrate the potential of 1-benzazepin-2-ones for in vivo imaging.
Collapse
Affiliation(s)
- Carlos Pérez-Medina
- Department of Chemistry and Institute of Nuclear Medicine, UCL, 235 Euston Road (T-5), NW1 2BU London, United Kingdom
| | | | | | | | | | | |
Collapse
|
48
|
Pérez-Medina C, López C, Pilar Cabildo M, Claramunt RM, Carmen Torralba M, Rosario Torres M, Alkorta I, Elguero J. The tautomerism of fluorinated indazolinones in the solid state. J Mol Struct 2012. [DOI: 10.1016/j.molstruc.2012.04.049] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
49
|
López C, Claramunt RM, Cabildo MP, Pérez-Medina C, Torralba MC, Torres MR. SSNMR spectroscopy and X-ray crystallography of fluorinated indazolinones. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311079311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
50
|
Claramunt RM, López C, López A, Pérez-Medina C, Pérez-Torralba M, Alkorta I, Elguero J, Escames G, Acuña-Castroviejo D. Synthesis and biological evaluation of indazole derivatives. Eur J Med Chem 2011; 46:1439-47. [DOI: 10.1016/j.ejmech.2011.01.027] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2010] [Revised: 01/11/2011] [Accepted: 01/14/2011] [Indexed: 10/18/2022]
|